Research activity information

• Azacitidine treatment for myeloid leukemia associated with Down syndrome: A nationwide retrospective study in Japan

  Shota Kato, Kentaro Nakashima, Genki Yamato, Shoji Saito, Yuichi Taneyama, Nobuyuki Yamamoto, Takako Miyamura, Keisuke Kato, Yuya Sato, Ai Yamada, Takahiro Kamiya, Takuro Nishikawa, Suguru Uemura, Daisuke Tomizawa, Hiroshi Moritake, Kiminori Terui, Takashi Taga, Daisuke Hasegawa

  Abstract Hypomethylating agent treatment for myeloid leukemia associated with Down syndrome (ML‐DS) has been scarcely reported. Herein, we collected information on azacitidine treatment for ML‐DS in Japan. Forty‐eight cycles of azacitidine treatment were performed for 12 patients, including 11 relapsed or refractory (R/R) patients. In 40 cycles, azacitidine was used as monotherapy. No azacitidine‐related death was observed. One cycle concurrently administered with methotrexate‐based intrathecal therapy was discontinued due to toxicities. Only 4 of the 19 cycles given in non‐remission achieved complete or partial remission. In conclusion, although most toxicities were acceptable, azacitidine monotherapy might be insufficient for R/R ML‐DS cases.

  Wiley, Aug. 2024, Pediatric Blood & Cancer, 71(10) (10)

  Scientific journal


• 本邦における小児がん患者に対する口腔ケアの現状

  山本 暢之, 大曽根 眞也, 鈴木 孝二, 篠田 邦大, 斎藤 雄弥, 澤田 明久, 石田 裕二, 森 尚子, 加藤 陽子, 新小田 雄一, 嘉数 真理子, 佐野 弘純, 矢野 道広, 水谷 修紀, 福島 啓太郎

  【背景】小児がん治療中の口腔粘膜障害について,国内での予防や治療の現状は不明である.そこで日本小児がん研究グループ(JCCG)参加施設における現状調査を行った.【方法】JCCG参加153施設を対象に2017年4月から7月まで,口腔粘膜障害の予防と治療についてウェブアンケート調査を行った.【結果】108施設(71%),110診療科から回答を得た.医師だけではなく看護師,歯科医師,歯科衛生士が中心となり,多職種による口腔ケアが行われていた.72%の診療科で小児がん患者への口腔ケアの指導が行われ,65%の診療科で含嗽とブラッシングを併用した口腔ケアが行われていた.クライオセラピーは64%の診療科で経験があり,うちメルファラン投与時に行う診療科が84%と最も多かった.口腔粘膜障害による疼痛に対してアセトアミノフェン,非ステロイド性消炎鎮痛剤,オピオイドなどが使用されていた.【考察】小児がん患者に対する口腔ケアが国内で標準化されていないことが明らかとなった.更なる口腔ケアの向上に向けた研究が必要である.(著者抄録)

  (一社)日本小児血液・がん学会, Jul. 2024, 日本小児血液・がん学会雑誌, 61(2) (2), 176 - 183, Japanese


• Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients

  Naoko Nakatani, Kaung Htet Nay Win, Mon Cho Yee, Tomoko Fujikawa, Suguru Uemura, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Shotaro Inoue, Akihiro Nishimura, Nanako Nino, Akihiro Tamura, Nobuyuki YAMAMOTO, Kandai Nozu, Noriyuki Nishimura

  May 2024, Biology

  Scientific journal


• 国産手術支援ロボットhinotoriによるロボット支援下左副腎褐色細胞腫摘出術を行った1例

  大片 祐一, 古川 順也, 坊 亮輔, 口分田 啓, 亀岡 泰幸, 岩渕 瀬怜奈, 高成田 祐希, 冨岡 雄一郎, 鮫島 由友, 中井 優美子, 山本 暢之, 中野 雄造, 野津 寛大, 尾藤 祐子

  (公社)日本小児科学会, Apr. 2024, 日本小児科学会雑誌, 128(4) (4), 631 - 632, Japanese


• 潰瘍性大腸炎の発症時に免疫性血小板減少症を合併した1例

  今川 幸人, 堀之内 智子, 近藤 淳, 岡本 典大, 宮崎 はる香, 田中 悠, 市川 裕太, 上田 知佳, 北角 英晶, 田村 彰広, 渡邉 大輔, 山本 暢之, 榊原 菜々, 大井 充, 星 奈美子, 児玉 祐三, 野津 寛大

  (公社)日本小児科学会, Apr. 2024, 日本小児科学会雑誌, 128(4) (4), 624 - 624, Japanese


• 小児脛骨に発症したBCG骨髄炎の1例

  中松 裕太, 原 仁美, 澤田 良子, 山本 暢之, 秋末 敏宏, 黒田 良祐

  (一社)中部日本整形外科災害外科学会, Apr. 2024, 中部日本整形外科災害外科学会雑誌, 67(春季学会) (春季学会), 175 - 175, Japanese


• 国産手術支援ロボットhinotoriによるロボット支援下左副腎褐色細胞腫摘出術を行った1例

  大片 祐一, 古川 順也, 坊 亮輔, 口分田 啓, 亀岡 泰幸, 岩渕 瀬怜奈, 高成田 祐希, 冨岡 雄一郎, 鮫島 由友, 中井 優美子, 山本 暢之, 中野 雄造, 野津 寛大, 尾藤 祐子

  (公社)日本小児科学会, Apr. 2024, 日本小児科学会雑誌, 128(4) (4), 631 - 632, Japanese


• A novel NFKB1 variant in a Japanese pedigree with common variable immunodeficiency

  Naoko Nakatani, Akihiro Tamura, Hiroaki Hanafusa, Nanako Nino, Nobuyuki Yamamoto, Hiroyuki Awano, Yasuhiro Tanaka, Naoya Morisada, Suguru Uemura, Atsuro Saito, Daiichiro Hasegawa, Kandai Nozu, Yoshiyuki Kosaka

  Mar. 2024, Human Genome Variation

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 小児がん支持療法と関連する外科治療 吸収性スペーサー留置術 神戸大学における経験と小児領域への応用

  大片 祐一, 小松 昇平, 出水 祐介, 山本 暢之, 佐々木 良平, 福本 巧, 尾藤 祐子

  腹部悪性腫瘍に対する粒子線治療は,腫瘍に近接する消化管の放射線障害が大きな問題となり,根治的線量の照射が困難な場合がある.この治療限界を克服すべく,神戸大学では粒子線照射前の準備として開腹下に腫瘍と消化管の間に延伸ポリテトラフルオロエチレン(ePTFE)製シート(以下,ePTFE製シート)を挿入するスペーサー留置術を考案し,2006年8月から2022年3月までに腹部悪性腫瘍200例以上に対して施行し良好な治療成績を報告してきた.さらに不織布型の吸収性スペーサーの開発に取り組み,放射線治療用吸収性組織スペーサー「ネスキープ」の上市に至り,2019年6月から2022年3月までに50例以上のネスキープ留置術を施行した.ネスキープの長所はePTFE製シートに比して素材が柔軟であり,離断・連結が容易で腫瘍に即した形状に作成して腫瘍と臓器の間に固定しやすいことである.また吸収性素材であるため消化管合併切除・感染症例などに対してもスペーサー留置術の適応が拡大される可能性がある.ネスキープ留置術における手術手技の取り組みを供覧し,小児領域への応用も含めて吸収性スペーサー留置術の今後の課題について報告する.(著者抄録)

  (一社)日本小児血液・がん学会, Mar. 2024, 日本小児血液・がん学会雑誌, 60(5) (5), 297 - 300, Japanese


• 持続する右下肢痛で発症した骨肉腫の1例

  伊藤 立人, 川村 葵, 曽根原 晶子, 西村 明紘, 洪 聖媛, 鮫島 智大, 花房 宏昭, 老川 静香, 徳元 翔一, 山口 宏, 坊 亮輔, 山本 暢之, 永瀬 裕朗

  (一社)日本小児神経学会, Mar. 2024, 脳と発達, 56(2) (2), 152 - 152, Japanese


• 小児がん支持療法と関連する外科治療 吸収性スペーサー留置術 神戸大学における経験と小児領域への応用

  大片 祐一, 小松 昇平, 出水 祐介, 山本 暢之, 佐々木 良平, 福本 巧, 尾藤 祐子

  (一社)日本小児血液・がん学会, Mar. 2024, 日本小児血液・がん学会雑誌, 60(5) (5), 297 - 300, Japanese


• MGMTタンパク発現は骨肉腫に対するテモゾロミド併用化学療法の治療効果予測に有用なバイオマーカーとなりうる(MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy against osteosarcoma)

  内原 嘉仁, 梅田 雄嗣, 赤澤 嶺, 窪田 博仁, 才田 聡, 加藤 格, 平松 英文, 山田 洋介, 荒川 歩, 山本 暢之, 細谷 要介, 植村 優, 佐野 秀樹, 多賀 崇, 滝田 順子

  (公社)日本小児科学会, Feb. 2024, 日本小児科学会雑誌, 128(2) (2), 238 - 238, English


• MGMTタンパク発現は骨肉腫に対するテモゾロミド併用化学療法の治療効果予測に有用なバイオマーカーとなりうる(MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy against osteosarcoma)

  内原 嘉仁, 梅田 雄嗣, 赤澤 嶺, 窪田 博仁, 才田 聡, 加藤 格, 平松 英文, 山田 洋介, 荒川 歩, 山本 暢之, 細谷 要介, 植村 優, 佐野 秀樹, 多賀 崇, 滝田 順子

  (公社)日本小児科学会, Feb. 2024, 日本小児科学会雑誌, 128(2) (2), 238 - 238, English


• Alteration of long and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis

  Katsuyuki Nishi, Taro Sakamaki, Akiomi Nagasaka, Kevin S. Kao, Kay Sadaoka, Masahide Asano, Nobuyuki Yamamoto, Akifumi Takaori-Kondo, Masanori Miyanishi

  Jan. 2024


• Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.

  Shotaro Inoue, Kaung Htet Nay Win, Cho Yee Mon, Tomoko Fujikawa, Sayaka Hyodo, Suguru Uemura, Toshiaki Ishida, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Akihiro Nishimura, Naoko Nakatani, Nanako Nino, Akihiro Tamura, Nobuyuki Yamamoto, Kandai Nozu, Noriyuki Nishimura

  More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by quantitating neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow (BM) and peripheral blood (PB) samples. Although several sets of NB-mRNAs have been shown to possess a prognostic value for MRD in BM samples (BM-MRD), MRD in PB samples (PB-MRD) is considered to be low and difficult to evaluate. The present report describes an HR-NB case presenting higher PB-MRD than BM-MRD before 1st and 2nd relapse/regrowth. A 3-year-old female presented with an abdominal mass, was diagnosed with HR-NB, and treated according to the nationwide standard protocol for HR-NB. Following systemic induction and consolidation therapy with local therapy, the patient achieved complete remission but experienced a 1st relapse/regrowth 6 months after maintenance therapy. The patient partially responded to salvage chemotherapy and anti-GD2 immunotherapy but had a 2nd relapse/regrowth 14 months after the 1st relapse/regrowth. Consecutive PB-MRD and BM-MRD monitoring revealed that PB-MRD was lower than BM-MRD at diagnosis (100 times) and 1st and 2nd relapse/regrowth (1,000 and 3 times) but became higher than BM-MRD before 1st and 2nd relapse/regrowth. The present case highlights that PB-MRD can become higher than BM-MRD before relapse/regrowth of patients with HR-NB.

  Sep. 2023, Oncology letters, 26(3) (3), 369 - 369, English, International magazine


• 汎血球減少と斜指を契機に診断したMECOM関連症候群の女児

  平場 裕美, 二野 菜々子, 相馬 健人, 増田 知佳, 北角 英晶, 中谷 尚子, 呉 東祐, 高寺 明弘, 田村 彰広, 山本 暢之, 森沢 猛, 西村 範行, 野津 寛大

  (公社)日本小児科学会, Apr. 2023, 日本小児科学会雑誌, 127(4) (4), 625 - 625, Japanese


• 血性鼻汁をきっかけに診断したLCHの男児

  石川 達大, 井上 翔太郎, 西村 明紘, 中谷 尚子, 二野 菜々子, 田村 彰広, 山本 暢之, 西村 範行, 野津 寛大

  (公社)日本小児科学会, Apr. 2023, 日本小児科学会雑誌, 127(4) (4), 632 - 632, Japanese


• 一過性の細胞免疫不全所見を認めた超早期発症型炎症性腸疾患の1例

  福田 拓弥, 堀之内 智子, 近藤 淳, 宮崎 はる香, 田村 彰広, 大片 祐一, 増田 知佳, 北角 英晶, 具 潤亜, 渡邉 大輔, 星 奈美子, 榊原 菜々, 山本 暢之, 大井 充, 尾藤 祐子, 森 一越, 野津 寛大

  (公社)日本小児科学会, Apr. 2023, 日本小児科学会雑誌, 127(4) (4), 625 - 626, Japanese


• Current methods of preventing infectious disease and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan.

  Shinya Osone, Kunihiro Shinoda, Nobuyuki Yamamoto, Koji Suzuki, Michihiro Yano, Yuji Ishida, Yuya Saito, Akihisa Sawada, Hirozumi Sano, Yoko Kato, Yuichi Shinkoda, Mariko Kakazu, Naoko Mori, Shuki Mizutani, Keitaro Fukushima

  BACKGROUND: Preventing infection and managing febrile neutropenia (FN) is mandatory for children with cancer undergoing chemotherapy. However, the current situation in Japan is unknown. METHODS: We conducted a nationwide web-based questionnaire survey in 153 institutions treating childhood cancer in Japan. We asked about the type prophylaxis used to prevent infectious disease and manage FN. If patients with childhood cancer were managed by both pediatricians and surgeons at the same institution, we asked both to reply. RESULTS: We received replies from 117 departments at 111 centers: of these, 108 were from pediatricians. Laminar air flow for neutropenic patients, and frequent hand sanitization with ethanol, were widespread. Twenty-eight percent and forty percent of departments performed active surveillance by taking cultures from patients and the environment, respectively, before initiation of chemotherapy. Forty-four percent of departments administered prophylactic intravenous antibiotics according to patient status. Many departments measured serum (1,3)-β-D glucan, procalcitonin, and aspergillus galactomannan at the onset of FN. Twenty-eight percent of departments used carbapenem as empirical therapy for FN. Some departments used prophylactic granulocyte-colony stimulating factor for acute leukemia. Seventy-two percent of departments used prophylactic immunoglobulin for hypogammaglobinemia caused by chemotherapy. Palivizumab was administered widely for respiratory syncytial virus prophylaxis in immunocompromised infants. CONCLUSION: As a whole, intensive care for infectious prophylaxis or FN is applied in Japan; however, the methods vary among centers, and some are excessive or inadequate. Therefore, it is desirable to conduct clinical trials and establish adequate care protocols for infection in children with cancer in Japan.

  Feb. 2023, International journal of clinical oncology, 28(2) (2), 331 - 340, English, Domestic magazine

  Scientific journal


• COVID-19を契機に溶血発作を発症したグルコース6リン酸脱水素酵素欠損症

  上杉 裕紀, 井上 翔太郎, 今川 幸人, 西村 明紘, 中谷 尚子, 二野 菜々子, 田村 彰広, 山本 暢之, 西村 範行, 野津 寛大

  グルコース6リン酸脱水素酵素(G6PD)欠損症は赤血球酵素異常の中で最も頻度が高く,世界で4億人の患者がいるとされるが本邦での有病率は0.1%未満と少ない。感染症や特定の薬剤投与での酸化ストレスにより溶血発作が生じる。症例は当院でフォロー中のG6PD欠損症の18歳男性で,受診2日前から発熱し,受診当日の朝,排尿中に意識消失し自宅で倒れているところを発見され当院に救急搬送された。SARS-CoV-2陽性,Hgb6.6g/dL,LDH 1,894U/L,ハプトグロビン7mg/dLからCOVID-19に伴う溶血発作と診断し赤血球輸血を行った。輸血後全身状態は改善するも,その後も貧血は進行し解熱するまでの間に計6単位の赤血球輸血を要した。我々が知る限り,本症例が本邦でCOVID-19を契機に溶血発作を生じた初の報告である。G6PD欠損症患者は溶血発作,血栓傾向など重症化リスクが高いためCOVID-19発症時には慎重な対応が重要である。(著者抄録)

  兵庫県小児科医会, 2023, 兵庫県小児科医会報, (79) (79), 13 - 17, Japanese


• Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome.

  Masahiro Irie, Tetsuya Niihori, Tomohiro Nakano, Tasuku Suzuki, Saori Katayama, Kunihiko Moriya, Hidetaka Niizuma, Nobu Suzuki, Yuka Saito-Nanjo, Masaei Onuma, Takeshi Rikiishi, Atsushi Sato, Mayumi Hangai, Mitsuteru Hiwatari, Junji Ikeda, Reo Tanoshima, Norio Shiba, Yuki Yuza, Nobuyuki Yamamoto, Yoshiko Hashii, Motohiro Kato, Junko Takita, Miho Maeda, Yoko Aoki, Masue Imaizumi, Yoji Sasahara

  Mutations in the MECOM encoding EVI1 are observed in infants who have radioulnar synostosis with amegakaryocytic thrombocytopenia. MECOM-associated syndrome was proposed based on clinical heterogeneity. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for progressive bone marrow failure. However, data regarding allogeneic HSCT for this rare disease are limited. We retrospectively assessed overall survival, conditioning regimen, regimen-related toxicities and long-term sequelae in six patients treated with allogeneic HSCT. All patients received a reduced-intensity conditioning (RIC) regimen consisting of fludarabine, cyclophosphamide or melphalan, and rabbit anti-thymocyte globulin and/or low-dose total body/thoracic-abdominal/total lymphoid irradiation, followed by allogeneic bone marrow or cord blood transplantation from unrelated donors between 4 and 18 months of age. All patients survived and achieved stable engraftment and complete chimerization with the donor type. Moreover, no patient experienced severe regimen-related toxicities, and only lower grades of acute graft-versus-host disease were observed. Three patients treated with low-dose irradiation had relatively short stature compared to three patients not treated with irradiation. Therefore, allogeneic HSCT with RIC is an effective and feasible treatment for infants with MECOM-associated syndrome. Future studies are needed to evaluate the use of low-dose irradiation to avoid risks of other long-term sequelae.

  Dec. 2022, International journal of hematology, 117(4) (4), 598 - 606, English, Domestic magazine

  Scientific journal


• Spindle cell sarcoma with KIAA1549-BRAF resembling infantile fibrosarcoma morphologically: A case report and literature review.

  Tomoko Fujikawa, Suguru Uemura, Makiko Yoshida, Sayaka Hyodo, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Toshiaki Ishida, Takeshi Mori, Ayano Uematsu, Keiichi Morita, Tadashi Hatakeyama, Akihiro Tamura, Nobuyuki Yamamoto, Masato Komatsu, Toshinori Soejima, Daiichiro Hasegawa, Yoshiyuki Kosaka

  Infantile fibrosarcoma (IFS) commonly harbors ETS variant transcription factor 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) fusion. However, the recent accessibility to clinical next-generation sequencing (NGS) has revealed ETV6-NTRK3 negative spindle cell sarcomas resembling IFS morphologically, involving NTRK1/2, MET, RET and BRAF. The present report describes a pediatric case of spindle cell sarcoma with KIAA1549-BRAF resembling IFS morphologically. A 20-month-old female patient was referred to Kobe Children's Hospital (Kobe, Japan) for the treatment of intrathoracic spindle cell sarcoma. Pathologically, the intrathoracic tumor cells were composed of spindle cells with focal hemagiopericytomatous pattern. In immunohistochemistry analysis, the intrathoracic tumor cells focally expressed desmin and WT-1 and were negative for pan-tropomyosin receptor kinase (TRK), S-100 and CD34. Fluorescence in situ hybridization analysis for ETV6 and capicua transcriptional repressor revealed negative split signals. Although the patient was initially diagnosed with IFS morphologically, KIAA1549-BRAF fusion transcript was detected by comprehensive genomic profiling with NGS using intrathoracic tumor tissues and confirmed by reverse transcription-PCR. Chemotherapy induced a reduction in the tumor size. At present, the patient is alive with the disease and has been receiving therapy for 8 months since the initiation of chemotherapy. Review of BRAF-altered spindle cell sarcomas resembling IFS morphologically revealed the inconsistency in immunohistochemical expression patterns and the diversity of BRAF fusion genes and mutations. Therefore, the elucidation of genomic profiling by NGS may assist in making an appropriate diagnosis and selecting novel alternative therapies in ETV6-NTRK3-negative spindle cell sarcomas resembling IFS morphologically.

  Dec. 2022, Oncology letters, 24(6) (6), 452 - 452, English, International magazine


• Minimal residual disease detected by droplet digital PCR in peripheral blood stem cell grafts has a prognostic impact on high-risk neuroblastoma patients.

  Nanako Nino, Toshiaki Ishida, Naoko Nakatani, Kyaw San Lin, Kaung Htet Nay Win, Cho Yee Mon, Akihiro Nishimura, Shotaro Inoue, Akihiro Tamura, Nobuyuki Yamamoto, Suguru Uemura, Atsuro Saito, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Kandai Nozu, Noriyuki Nishimura

  More than half of high-risk neuroblastoma (NB) patients have experienced relapse due to the activation of chemoresistant minimal residual disease (MRD) even though they are treated by high-dose chemotherapy with autologous peripheral blood stem cell (PBSC) transplantation. Although MRD in high-risk NB patients can be evaluated by quantitative PCR with several sets of neuroblastoma-associated mRNAs (NB-mRNAs), the prognostic significance of MRD in PBSC grafts (PBSC-MRD) is unclear. In the present study, we collected 20 PBSC grafts from 20 high-risk NB patients and evaluated PBSC-MRD detected by droplet digital PCR (ddPCR) with 7NB-mRNAs (CRMP1, DBH, DDC, GAP43, ISL1, PHOX2B, and TH mRNA). PBSC-MRD in 11 relapsed patients was significantly higher than that in 9 non-relapsed patients. Patients with a higher PBSC-MRD had a lower 3-year event-free survival (P = 0.0148). The present study suggests that PBSC-MRD detected by ddPCR with 7NB-mRNAs has a prognostic impact on high-risk NB patients.

  Oct. 2022, Heliyon, 8(10) (10), e10978, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 小児科医の意識調査 大事にする価値観は?兵庫県で次に取り組むべき課題は?

  西山 将広, 山本 暢之, 堀之内 智子, 藤岡 一路, 永瀬 裕朗, 野津 寛大

  (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 557 - 557, Japanese


• 兵庫県における治療可能となった難病に対する拡大新生児マススクリーニングの取り組み

  粟野 宏之, 坊 亮輔, 山本 暢之, 李 知子, 上田 雅章, 野津 寛大, 竹島 泰弘, 飯島 一誠

  (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 547 - 547, Japanese


• 5歳児検尿を契機に発見されたSchimke症候群の1例

  川村 達也, 藤井 順子, 吉本 啓修, 大西 徳子, 権東 雅宏, 梁川 裕司, 横山 直樹, 山本 暢之, 野津 寛大, 吉川 徳茂

  (公社)日本小児科学会, Mar. 2022, 日本小児科学会雑誌, 126(3) (3), 547 - 547, Japanese


• Reliability and Validity of the Japanese Pediatric Version of Memorial Symptom Assessment Scale.

  Tomomi Hayase, Makiko N Mieno, Kyoko Kobayashi, Naoko Mori, Adam Jon Lebowitz, Yoko Kato, Yuya Saito, Yuki Yuza, Hirozumi Sano, Shinya Osone, Tsukasa Hori, Yuichi Shinkoda, Nobuyuki Yamamoto, Daiichiro Hasegawa, Michihiro Yano, Miho Ashiarai, Daisuke Hasegawa, Akihisa Sawada, Takuhiro Yamaguchi, Akira Morimoto, Keitaro Fukushima

  CONTEXT: Few instruments in Japanese assess health-related quality of life in pediatric cancer patients. OBJECTIVES: To translate the Memorial Symptom Assessment Scale (MSAS) into Japanese pediatric and proxy versions (MSAS-J 7-12, MSAS-J 13-18, and MSAS-J-Proxy) and assess validity and reliability. METHODS: Phase I comprised forward-backward translation and pilot testing in 13 children and 16 guardians. Phase II consisted of psychometric testing of the three MSAS-J versions in 164 children and 238 guardians. Internal consistency, test-retest reliability, and construct and known-group validity of the MSAS-J were assessed. RESULTS: Cronbach's alpha coefficients for the total and subscale scores were over 0.70, excluding the psychological symptom (PSYCH) subscale score of the MSAS-J 7-12. Most MSAS-J scores significantly inversely correlated with two versions of the Pediatric Quality of Life Inventory. A strong child-guardian correlation was shown in the total and subscale scores (ICC range 0.66-0.83). Kappa estimates showed acceptable child-guardian symptom agreement. MSAS-J 7-12 and proxy differentiated patients according to clinical status. CONCLUSION: MSAS-J is a reliable and valid instrument to assess symptoms among Japanese children with cancer.

  Jan. 2022, Journal of pain and symptom management, 63(5) (5), e495-e504, English, International magazine

  Scientific journal


• Multivariate analysis of the impact of weather and air pollution on emergency department visits for unprovoked seizure among children: A retrospective clinical observational study.

  Hiroshi Yamaguchi, Kandai Nozu, Shinya Ishiko, Atsushi Kondo, Nobuyuki Yamamoto, Akihiro Tamura, Yuya Aoto, Ai Unzaki, Kazuto Ishibashi, Ichiro Morioka, Hiroaki Nagase, Akihito Ishida

  BACKGROUND: An unprovoked seizure is a seizure or a cluster of seizures occurring within 24 h in a patient older than 1 month of age without precipitating factors. Recent studies have reported that extrinsic factors, such as meteorological conditions and air pollutants, may be important in seizure occurrence. Thus, this study aimed to examine the association between the number of visits to the emergency department (ED) by children for nighttime unprovoked seizures and exposure to multi-faceted factors, such as meteorological conditions and air pollution. METHODS: We conducted a clinical observational analysis and reviewed consecutive patients younger than 16 years of age who visited the primary ED center in Kobe City, Japan, during nighttime (7:30 p.m.-7:00 a.m.) between January 1, 2011 and December 31, 2015. We investigated the effects of meteorological factors and air pollutants on the number of patients with unprovoked seizures using multivariate analysis of Poisson regression estimates. RESULTS: In total, 151,119 children visited the ED, out of which 97 patients presented with unprovoked seizures. The mean age of the patients was 4.7 years (range, 1 month to 15.3 years), and 54.6% of them were boys. The total number of patients with unprovoked seizures showed no significant changes with the seasons; however, there were dominant peaks during the fall and fewer visits during the summer. The multivariate analysis of Poisson regression estimates revealed a significant positive relationship between the number of patients presenting with unprovoked seizures and precipitation (+1 patient/87 mm; p = 0.03) and methane (+1 patient/0.14 ppm; p = 0.03) levels and a negative relationship between the number of patients presenting with unprovoked seizures and nitrogen dioxide level (-1 patient/0.02 ppm; p = 0.04). CONCLUSIONS: The present study is the first to evaluate the association between the number of children who presented to the ED with nighttime unprovoked seizures and environmental factors after controlling for confounding factors.

  Dec. 2021, Epilepsy & behavior : E&B, 125, 108434 - 108434, English, International magazine

  Scientific journal


• 当科における小児造血細胞移植患者の精子保存(The sperm preservation in pediatric patients who underwent hematopoietic stem cell transplantation)

  藤川 朋子, 植村 優, 中谷 尚子, 二野 菜々子, 山本 暢之, 西村 範行, 岡田 桂輔, 千葉 公嗣, 塩谷 雅英, 飯島 一誠

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 2, English


• The sperm preservation in pediatric patients who underwent hematopoietic stem cell transplantation(和訳中)

  藤川 朋子, 植村 優, 中谷 尚子, 二野 菜々子, 山本 暢之, 西村 範行, 岡田 桂輔, 千葉 公嗣, 塩谷 雅英, 飯島 一誠

  (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 2, English


• 本邦における小児がん患者の食事栄養管理に関する現状 JCCG施設調査より

  鈴木 孝二, 福島 啓太郎, 山本 暢之, 篠田 邦大, 矢野 道広, 石田 裕二, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 森 尚子, 福澤 正洋, 日本小児がん研究グループ(JCCG)支持療法委員会

  【目的】本邦の小児がん患者に対する化学療法中の食事栄養管理指針の作成に向けて,現状を把握するための全国調査を行った.【方法】2017年4月～7月に日本小児がん研究グループ(Japan Children's Cancer Group;JCCG)支持療法委員会より参加153施設の診療担当者に対してSurvey Monkeyを利用した食事栄養管理に関するWeb調査を実施した.【結果】調査対象となった153施設のうち110施設(72%)112診療科(内科系106診療科,外科系6診療科)から有効回答を得た.ほとんどの診療科で化学療法中に食事制限が行われ,その開始時期は「化学療法開始時から」が47%,「好中球500/μL未満から」が46%であった.持ち込み食は条件付きを含め90%の診療科で許可されていた.非加熱食品は制限されることが多かったが,牛乳,発酵飲料,密封されている惣菜や弁当,家人の手料理については対応が分かれた.栄養士または栄養サポートチームがいる診療科であっても,全ての患者に介入しているのは4割程度だった.【考察】小児がん診療における食事栄養管理について,本邦で施設によるばらつきが大きいことが分かった.今後,JCCG参加施設間で共有可能な指針が必要と考えられた.(著者抄録)

  (一社)日本小児血液・がん学会, Aug. 2021, 日本小児血液・がん学会雑誌, 58(2) (2), 175 - 181, Japanese


• 本邦における小児がん患者の食事栄養管理に関する現状 JCCG施設調査より

  鈴木 孝二, 福島 啓太郎, 山本 暢之, 篠田 邦大, 矢野 道広, 石田 裕二, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 森 尚子, 福澤 正洋, 日本小児がん研究グループ(JCCG)支持療法委員会

  (一社)日本小児血液・がん学会, Aug. 2021, 日本小児血液・がん学会雑誌, 58(2) (2), 175 - 181, Japanese


• Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.

  Kyaw San Lin, Suguru Uemura, Khin Kyae Mon Thwin, Naoko Nakatani, Toshiaki Ishida, Nobuyuki Yamamoto, Akihiro Tamura, Atsuro Saito, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, China Nagano, Satoru Takafuji, Kazumoto Iijima, Noriyuki Nishimura

  Neuroblastoma (NB) is the most common extracranial solid tumor in children and originates from sympathoadrenal or Schwann cell precursors derived from neural crest. These neural crest derivatives also constitute the hematopoietic and mesenchymal stem cells in bone marrow (BM) that is the most frequent site of NB metastasis and relapse. In NB patients, NB cells have been pathologically detected in BM and peripheral blood (PB), and minimal residual disease (MRD) in BM and PB (BM-MRD and PB-MRD) can be monitored by quantitating several sets of NB-associated mRNAs (NB-mRNAs). Although previous studies have shown varying degrees of correlation between BM-MRD and PB-MRD, the underlying factors and/or mechanisms remains unknown. In the present study, we determined the levels of BM-MRD and PB-MRD by quantitating seven NB-mRNAs in 133 pairs of concurrently collected BM and PB samples from 19 high-risk NB patients with clinical disease evaluation, and examined their correlation in overall and subgroups of sample pairs. The levels of BM-MRD and PB-MRD were moderately (r = 0.418, p < 0.001) correlated with each other in overall sample pairs. The correlation became strong (r = 0.725, p < 0.001), weak (r = 0.284, p = 0.008), and insignificant (p = 0.194) in progression, stable, and remission subgroups of sample pairs, respectively. It also became stronger in subgroups of sample pairs with poor treatment responses and poor prognostic factors. Present study suggests that MRD in high-risk NB shows a dynamic and disease burden-dependent correlation between BM and PB.

  Aug. 2021, Translational oncology, 14(8) (8), 101019 - 101019, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency.

  Shintaro Ono, Kozue Takeshita, Yuko Kiridoshi, Motohiro Kato, Takahiro Kamiya, Akihiro Hoshino, Masakatsu Yanagimachi, Katsuhiro Arai, Ichiro Takeuchi, Nariaki Toita, Toshihiko Imamura, Yoji Sasahara, Junichi Sugita, Kazuko Hamamoto, Masanobu Takeuchi, Shoji Saito, Masaei Onuma, Hiroshi Tsujimoto, Masahiro Yasui, Takashi Taga, Yuki Arakawa, Yuichi Mitani, Nobuyuki Yamamoto, Kohsuke Imai, Wataru Suda, Masahira Hattori, Osamu Ohara, Tomohiro Morio, Kenya Honda, Hirokazu Kanegane

  BACKGROUND: X-linked inhibitor of apoptosis protein (XIAP) deficiency is an infrequent inborn error of immunity that is often associated with refractory inflammatory bowel disease (IBD). The natural course of XIAP deficiency is typically associated with poor prognosis, and hematopoietic cell transplantation (HCT) is the only curative treatment. OBJECTIVE: To study (1) the effect of HCT on patients with XIAP deficiency undergoing HCT, (2) the status of XIAP deficiency-associated IBD after HCT, and (3) the gut microbiota of XIAP deficiency-associated IBD before and after HCT. METHODS: A nationwide survey of patients with XIAP deficiency was conducted. A spreadsheet questionnaire was collected from the physicians. Feces samples collected from the patients before and after HCT and their healthy family members were analyzed. RESULTS: Twenty-six patients with XIAP deficiency underwent HCT by the end of March 2020, and 22 patients (84.6%) survived. All the survivors underwent a fludarabine-based reduced-intensity condition regimen. Acute graft-versus-host disease was observed in 17 patients (65.4%). Nineteen patients experienced refractory IBD before undergoing HCT. IBD improved remarkably after HCT. After HCT, the colonoscopic and pathological symptoms were restored to normal, and the pediatric ulcerative colitis activity index improved significantly. Gut microbiota indicated dysbiosis before HCT; however, it was improved to resemble that of the healthy family members after HCT. CONCLUSIONS: This study revealed that HCT has a favorable outcome for XIAP deficiency. HCT rescues gut inflammation and dysbiosis in patients with XIAP deficiency.

  Jul. 2021, The journal of allergy and clinical immunology. In practice, 9(10) (10), 3767 - 3780, English, International magazine

  Scientific journal


• Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.

  Suguru Uemura, Kyaw San Lin, Khin Kyae Mon Thwin, Naoko Nakatani, Toshiaki Ishida, Nobuyuki Yamamoto, Akihiro Tamura, Atsuro Saito, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, China Nagano, Satoru Takafuji, Kazumoto Iijima, Noriyuki Nishimura

  Vanillylmandelic acid (VMA), homovanillic acid (HVA), neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) are classical tumor markers and are used as standard clinical evaluations for patients with neuroblastoma (NB). Minimal residual disease (MRD) can be monitored by quantifying several sets of NB-associated mRNAs in the bone marrow (BM) and peripheral blood (PB) of patients with NB. Although MRD in BM and PB has been revealed to be a strong prognostic factor that is independent of standard clinical evaluations, its interrelation with tumor markers remains uncharacterized. The present study determined the levels of tumor markers (VMA, HVA, NSE and LDH) and MRD (BM-MRD and PB-MRD) in 133 pairs of concurrently collected BM, PB and urine samples from 19 patients with high-risk NB. The patients were evaluated during the entire course of treatment, which included 10 diagnoses, 32 treatments, 36 post-treatment, 9 relapses and 46 post-relapse sample pairs. The level of BM-MRD and PB-MRD was determined by quantifying 7 NB-mRNAs (collapsin response mediator protein 1, dopamine beta-hydroxylase, dopa decarboxylase, growth-associated protein 43, ISL LIM homeobox 1, pairedlike homeobox 2b and tyrosine hydroxylase) using droplet digital PCR. In overall sample pairs, tumor markers (VMA, HVA, NSE and LDH) demonstrated weak but significant correlations (P<0.011) with BM-MRD and PB-MRD. In subgroups according to each patient evaluation, the degree of correlation between tumor markers and MRD became stronger in patients with adrenal gland tumors, BM metastasis at diagnosis and relapse/regrowth compared with overall sample pairs. In contrast, tumor markers demonstrated variable correlations with MRD in subgroups according to each sample evaluation (BM infiltration at sampling, collection time point and disease status). The results suggested that tumor markers may demonstrate limited correlation with MRD in patients with high-risk NB.

  Jul. 2021, Molecular and clinical oncology, 15(1) (1), 137 - 137, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 癌ゲノム医療 神戸大学医学部附属病院におけるがんゲノム医療の現状と課題

  篠山 隆司, 田中 一寛, 金原 史朗, 小松 正人, 児玉 良典, 山本 暢之, 長嶋 宏明, 南 博信, 廣瀬 隆則, 伊藤 智雄

  日本脳腫瘍病理学会, May 2021, Brain Tumor Pathology, 38(Suppl.) (Suppl.), 067 - 067, Japanese


• 多発乳児血管腫に対するプロプラノロール投与

  金 潔駿, 二野 菜々子, 中谷 尚子, 植村 優, 山本 暢之, 西村 範行, 飯島 一誠, 野村 正, 松本 尚子, 佐伯 啓介

  (公社)日本小児科学会, Apr. 2021, 日本小児科学会雑誌, 125(4) (4), 681 - 681, Japanese


• Usefulness of functional splicing analysis to confirm precise disease pathogenesis in Diamond-Blackfan anemia caused by intronic variants in RPS19.

  Satoru Takafuji, Takeshi Mori, Noriyuki Nishimura, Nobuyuki Yamamoto, Suguru Uemura, Kandai Nozu, Kiminori Terui, Tsutomu Toki, Etsuro Ito, Hideki Muramatsu, Yoshiyuki Takahashi, Masafumi Matsuo, Tomohiko Yamamura, Kazumoto Iijima

  Diamond-Blackfan anemia (DBA) is mainly caused by pathogenic variants in ribosomal proteins and 22 responsible genes have been identified to date. The most common causative gene of DBA is RPS19 [NM_001022.4]. Nearly 180 RPS19 variants have been reported, including three deep intronic variants outside the splicing consensus sequence (c.72-92A > G, c.356 + 18G > C, and c.411 + 6G > C). We also identified one case with a c.412-3C > G intronic variant. Without conducting transcript analysis, the pathogenicity of these variants is unknown. However, it is difficult to assess transcripts because of their fragility. In such cases, in vitro functional splicing assays can be used to assess pathogenicity. Here, we report functional splicing analysis results of four RPS19 deep intronic variants identified in our case and in previously reported cases. One splicing consensus variant (c.411 + 1G > A) was also examined as a positive control. Aberrant splicing with a 2-bp insertion between exons 5 and 6 was identified in the patient samples and minigene assay results also identified exon 6 skipping in our case. The exon 6 skipping transcript was confirmed by further evaluation using quantitative RT-PCR. Additionally, minigene assay analysis of three reported deep intronic variants revealed that none of them showed aberrant splicing and that these variants were not considered to be pathogenic. In conclusion, the minigene assay is a useful method for functional splicing analysis of inherited disease.

  Feb. 2021, Pediatric hematology and oncology, 38(6) (6), 1 - 16, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 高リスク神経芽腫における微小残存病変(MRD)と腫瘍マーカーの相関に関する臨床的検討(Clinical analysis of the correlation between minimal residual disease and tumor markers in high-risk neuroblastoma)

  植村 優, Lin Kyaw San, Thwin Khin Kyaemon, 中谷 尚子, 石田 敏章, 山本 暢之, 田村 彰広, 斉藤 敦郎, 森 健, 長谷川 大一郎, 小阪 嘉之, 二野 菜々子, 高藤 哲, 青砥 悠哉, 長野 智那, 飯島 一誠, 西村 範行

  (公社)日本小児科学会, Feb. 2021, 日本小児科学会雑誌, 125(2) (2), 250 - 250, English


• Catheter-related blood stream infection caused by Mycobacterium chelonae in a child with myeloid leukemia associated with Down syndrome.

  Tomoko Fujikawa, Suguru Uemura, Yuya Aoto, Yoshinori Nambu, China Nagano, Naoko Nakatani, Nanako Nino, Nobuyuki Yamamoto, Takeshi Mori, Noriyuki Nishimura, Kazumoto Iijima

  Rapidly growing nontuberculous mycobacteria should be considered if GPRs gram-positive rods are detected in blood cultures 2-3 days after the blood sample collection.

  Feb. 2021, Clinical case reports, 9(2) (2), 835 - 840, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• A case of autoimmune enteropathy with CTLA4 haploinsufficiency.

  Haruka Miyazaki, Namiko Hoshi, Michitaka Kohashi, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Makoto Ooi, Nobuyuki Yamamoto, Suguru Uemura, Noriyuki Nishimura, Kazumoto Iijima, Keisuke Jimbo, Tsubasa Okano, Akihiro Hoshino, Kohsuke Imai, Hirokazu Kanegane, Ichiro Kobayashi, Yuzo Kodama

  Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and mutations in FOXP3, which is a master gene of regulatory T cells (Tregs), are major causes of AIE. Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype. We present the case of a 13-year-old girl with CTLA4 haploinsufficiency, suffering from recurrent immune thrombocytopenic purpura and intractable diarrhea. We detected an autoantibody to the AIE-related 75 kDa antigen (AIE-75), a hallmark of the IPEX syndrome, in her serum. She responded well to a medium dose of prednisolone and a controlled dose of 6-mercaptopurine (6-MP), even after the cessation of prednisolone administration. Serum levels of the soluble interleukin-2 receptor and immunoglobulin G (IgG) were useful in monitoring disease activity during 6-MP therapy. In conclusion, autoimmune-mediated mechanisms, similar to the IPEX syndrome, may be involved in the development of enteropathy in CTLA4 haploinsufficiency. Treatment with 6-MP and monitoring of disease activity using serum levels of soluble interleukin-2 receptor and IgG is suggested for such cases.

  Jan. 2021, Intestinal research, 20(1) (1), 144 - 149, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.

  Katsutsugu Umeda, Takako Miyamura, Kenji Yamada, Hideki Sano, Ako Hosono, Minako Sumi, Hajime Okita, Tadashi Kumamoto, Akira Kawai, Junya Hirayama, Ryoji Jyoko, Akihisa Sawada, Hideki Nakayama, Yosuke Hosoya, Naoko Maeda, Nobuyuki Yamamoto, Chihaya Imai, Daiichiro Hasegawa, Motoaki Chin, Toshifumi Ozaki

  BACKGROUND: Patients with Ewing's sarcoma family of tumors (ESFT) who experience relapse or progression have a poor prognosis. AIM: This study aimed to identify the prognostic and therapeutic factors affecting overall survival (OS) of patients with recurrent or refractory localized ESFT. METHODS AND RESULTS: Thirty-eight patients with localized ESFT who experienced first relapse or progression between 2000 and 2018 were retrospectively reviewed. The 5-year OS rate of the entire cohort was 48.3% (95% confidence interval, 29.9%-64.5%). Multivariate analysis of OS identified time to relapse or progression, but not stem cell transplantation (SCT), as the sole independent risk factor (hazard ratio, 35.8; P = .002). Among 31 patients who received salvage chemotherapy before local treatment, 21 received chemotherapy regimens that are not conventionally used for newly diagnosed ESFT. The objective response rate to first-line salvage chemotherapy was 55.2% in the 29 evaluable patients. Time to relapse or progression was significantly associated with response to first-line salvage chemotherapy (P = .006). CONCLUSIONS: The present study fails to demonstrate significant clinical benefit of SCT for recurrent or refractory localized ESFT. Recently established chemotherapy regimens may increase the survival rate of patients with recurrent or refractory localized ESFT while attenuating the beneficial effect of SCT.

  Jan. 2021, Cancer reports (Hoboken, N.J.), 4(3) (3), e1329, English, International magazine

  Scientific journal


• Early elevation of factor IX level in japanese brothers with Haemophilia B Leyden who are carrying c. -35 g > a mutations in the promoter region of F9.

  Akihiro Tamura, Keiko Shinozawa, Suguru Uemura, Sayaka Nakamura, Takahiro Fujiwara, Teppei Tahara, Nobuyuki Yamamoto, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Takashi Muramatsu, Kagehiro Amano, Katsuyuki Fukutake, Yoshiyuki Kosaka

  Jan. 2021, Haemophilia : the official journal of the World Federation of Hemophilia, 27(4) (4), e510-e512, English, International magazine


• Extranodal natural killer/T-cell lymphoma in an 11-year-old child.

  Takeshi Ninchoji, Junya Fujimura, Suguru Uemura, Nobuyuki Yamamoto, Kandai Nozu, Kazumoto Iijima

  Extranodal natural killer/T-cell lymphoma (ENKTL) is difficult to identify and diagnose appropriately. Positron emission tomography imaging is a crucial method that leads to precise diagnosis. A proper regimen including stem cell transplantation would possibly improve prognosis of advanced ENKTL.

  Dec. 2020, Clinical case reports, 8(12) (12), 3658 - 3660, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Soft tissue tumor with novel NR1D1-MAML1 fusion in a pediatric case.

  Masato Komatsu, Nobuyuki Yamamoto, Teruya Kawamoto, Yohei Kawakami, Hitomi Hara, Suguru Uemura, Noriyuki Nishimura, Toshihiro Akisue, Ryosuke Kuroda, Kazumoto Iijima, Naoe Jimbo, Maki Kanzawa, Kazuyoshi Kajimoto, Tomoo Itoh, Takanori Hirose

  We herein describe soft tissue tumor arising in the lower extremity of a pediatric patient. The tumor displayed a unique and wide range of histological features, sheet-like and cohesive growth pattern consisting of enlarged round to epithelioid atypical cells with a large alveolar and pseudopapillary histological architecture, focally mimicking alveolar soft part sarcoma and MiT family translocation renal cell carcinoma. Tumor cells were focally immunoreactive for cytokeratin, S-100, and EMA. RNA sequencing identified a novel in-frame NR1D1 (exon 5)-MAML1 (exon 2) gene rearrangement resulting in the formation of a putative chimeric protein containing the N-terminal C4-type zing finger domains of NR1D1 and the C-terminal MAML1 protein, which was confirmed by subsequent RT-PCR, Sanger sequencing, and FISH assay. To the best of our knowledge, NR1D1-MAML1 fusion has not yet been described in any neoplasms, suggesting the emergence of a novel tumor entity.

  Dec. 2020, Virchows Archiv : an international journal of pathology, 477(6) (6), 891 - 895, English, International magazine

  [Refereed]

  Scientific journal


• 本邦小児がん患者における症状評価尺度開発のための調査研究

  早瀬 朋美, 三重野 牧子, 福島 啓太郎, 森 尚子, 加藤 陽子, 足洗 美穂, 大曽根 眞也, 小林 京子, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 長谷川 大一郎, 長谷川 大輔, 堀 司, 矢野 道広, 山本 暢之, 湯坐 有希, 山口 拓洋, 森本 哲

  (NPO)日本緩和医療学会, Aug. 2020, Palliative Care Research, 15(Suppl.) (Suppl.), S259 - S259, Japanese


• 小児・若年の上咽頭癌3例の治療経験

  宮脇 大輔, 妹尾 悟史, 窪田 光, 川口 弘毅, 石原 武明, 植村 優, 山本 暢之, 今村 善宣, 清田 尚臣, 丹生 健一, 佐々木 良平

  (一社)日本頭頸部癌学会, Jul. 2020, 頭頸部癌, 46(2) (2), 168 - 168, Japanese


• Pharmacokinetic analysis for model-supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients.

  Kenji Kishimoto, Daiichiro Hasegawa, Kei Irie, Akira Okada, Sayaka Nakamura, Akihiro Tamura, Nobuyuki Yamamoto, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Shoji Fukushima, Yoshiyuki Kosaka

  This prospective observational study analyzed the pharmacokinetics of busulfan in Japanese children and evaluated the predicting accuracy of previous pediatric PPK models of busulfan. This study enrolled five patients (aged 2-12 years, BW 14-48 kg) receiving a busulfan-based conditioning regimen for hematopoietic stem cell transplantation at our hospital between January 2017 and December 2018. All patients received a 2-hour intravenous busulfan infusion four times daily for a total of 16 doses. After the infusions, 51 plasma samples were collected with the plasma busulfan concentration measured by liquid chromatography-tandem mass spectrometry. PPK model fitting was analyzed using the (%MPE) and the (%MAPE). Limited sampling strategies for estimating busulfan AUC were also evaluated. High interpatient variability was observed in the PK parameters. The most suitable PPK model that reflected our data was McCune's two-compartment model (%MPE -8.7, %MAPE 19.3). A combination sampling method using the busulfan concentration at 2 and 6 hours after the start of the first busulfan dose was found to be able to estimate AUC4 day . These results provide useful information on busulfan therapeutic drug monitoring in the Japanese pediatric population.

  Jun. 2020, Pediatric transplantation, 24(4) (4), e13696, English, International magazine

  [Refereed]

  Scientific journal


• 医療技術等国際展開推進事業 小児がんの診療能力強化(前編) 開発途上国における小児がん診療能力強化事業5年間のまとめ

  七野 浩之, 山中 純子, 鈴木 優里, 瓜生 英子, 加藤 元博, 寺島 慶太, 富沢 大輔, 松本 公一, 副島 俊典, 山本 暢之, 長谷川 大一郎, 西村 範行, 義岡 孝子, 上原 秀一郎, 望月 慎史, 浅妻 伴, 大野 孝, 堤 義之, 菱木 知郎, 米田 光宏

  産業開発機構(株), May 2020, 映像情報Medical, 52(5) (5), 40 - 45, Japanese


• Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma.

  Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima

  The outcomes of osteosarcoma with poor prognostic factors, such as poor responders, metastatic disease at diagnosis, and relapsed or refractory disease, are poor. We reviewed the clinical records of the patients diagnosed with osteosarcoma at our institute between 2004 and 2018 who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in our institute. Ten patients of osteosarcoma with poor responder, refractory status, and metastatic disease at diagnosis received high-dose chemotherapy followed by ASCT. Four patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of thiotepa and melphalan (MEL). Five patients underwent high-dose chemotherapy followed by ASCT with the conditioning regimen consisted of intravenous busulfan (BU) and MEL. One patient underwent tandem high-dose chemotherapy followed by ASCT with BU and MEL followed by carboplatin and etoposide. None of the ten patients died of regimen related toxicities. None of the five patients with poor responders who underwent high-dose chemotherapy followed by ASCT as part of consolidation therapy died of disease after ASCT. High-dose chemotherapy followed by ASCT might be effective for poor responders in osteosarcoma.

  May 2020, Pediatric hematology and oncology, 37(4) (4), 337 - 343, English, International magazine

  [Refereed]

  Scientific journal


• 当院における小児がん患者の妊孕性温存について

  植村 優, 京野 由紀, 二野 菜々子, 高藤 哲, 山本 暢之, 西村 範行, 岡田 桂輔, 千葉 公嗣, 塩谷 雅英, 飯島 一誠

  (公社)日本小児科学会, Feb. 2020, 日本小児科学会雑誌, 124(2) (2), 293 - 293, Japanese


• Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.

  Khin K M Thwin, Toshiaki Ishida, Suguru Uemura, Nobuyuki Yamamoto, Kyaw S Lin, Akihiro Tamura, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Satoru Takafuji, Kazumoto Iijima, Noriyuki Nishimura

  Monitoring of several sets of neuroblastoma-associated mRNAs (NB-mRNAs) by real-time quantitative PCR (qPCR) can be used to evaluate minimal residual disease in NB patients. Droplet digital PCR (ddPCR) is an adaption of qPCR that potentially provides simpler and more reproducible detection of low levels of mRNAs. However, whether minimal residual disease in NB patients can be monitored by ddPCR using a set of NB-mRNAs is not yet tested. In this study, 208 bone marrow (BM) and 67 peripheral blood samples were retrospectively collected from 20 high-risk NB patients with clinical disease evaluation at two Japanese centers between 2011 and 2018, and level of each NB-mRNA (CRMP1, DBH, DDC, GAP43, ISL1, PHOX2B, and TH mRNAs) was determined by ddPCR. Level of 7NB-mRNAs (defined as the combined signature of each NB-mRNA) was higher in BM than peripheral blood, but correlated significantly with each other. In accordance with disease burden, it varied with disease status (remission, stable, or progression) and collection time point (diagnosis, treatment, post-treatment, or relapse). In 73 post-treatment BM samples, it was significantly higher in 17 relapsed/regrown samples than in 56 nonrelapsed/nonregrown samples. Furthermore, ddPCR had a better prognostic value than qPCR in detecting 7NB-mRNAs in the same 73 post-treatment BM samples. This study suggests that ddPCR detection of 7NB-mRNAs is significantly associated with tumor relapse/regrowth in high-risk NB patients.

  Feb. 2020, The Journal of molecular diagnostics : JMD, 22(2) (2), 236 - 246, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• VitB12 Deficiency Anemia in an Infant Born to Ileum-resected Mother

  Kousaku Matsubara, Akiyoshi Naito, Akihiro Tamura, Nanako Nino, Nobuyuki Yamamoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Yosuke Shigematsu

  WILEY, Dec. 2019, PEDIATRIC BLOOD & CANCER, 66, S73 - S74, English

  [Refereed]


• Early posttransplant plasma ADAMTS13 activity reduction in stem cell transplantation: a prospective study of 46 pediatric patients.

  Kenji Kishimoto, Daiichiro Hasegawa, Keiichiro Kawasaki, Akihiro Tamura, Nobuyuki Yamamoto, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Yoshiyuki Kosaka

  Dec. 2019, Bone marrow transplantation, 54(12) (12), 1926 - 1929, English, International magazine

  [Refereed]


• Spontaneously Developed Undifferentiated Sarcoma and Rhabdomyosarcoma in mdx Mice

  Takafuji Satoru, Niba Emma, Khin Thwin, Yamamoto Nobuyuki, Awano Hiroyuki, Fukushima Shoji, Itoh Kyoko, Nishio Hisahide, Matsuo Masafumi, Kyaw Lin, Uemura Suguru, Iijima Kazumoto, Nishimura Noriyuki

  Dec. 2019, PEDIATRIC BLOOD & CANCER, 66, S117 - S118

  [Refereed]


• Vitamin B12 deficiency anemia in an exclusively breastfed infant born to an ileum-resected mother.

  Akihiro Tamura, Nanako Nino, Nobuyuki Yamamoto, Akiyoshi Naito, Kousaku Matsubara, Naoko Nakatani, Takayuki Ichikawa, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Yosuke Shigematsu, Daiichiro Hasegawa, Yoshiyuki Kosaka

  Oct. 2019, Pediatrics and neonatology, 60(5) (5), 579 - 580, English, International magazine

  [Refereed]

  Scientific journal


• Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma.

  Akihiro Tamura, Nobuyuki Yamamoto, Nanako Nino, Takayuki Ichikawa, Naoko Nakatani, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Makiko Yoshida, Yoshinobu Akasaka, Daiichiro Hasegawa, Yoshiyuki Kosaka

  The dismal prognosis of patients with disseminated Ewing sarcoma necessitates the development of novel treatment strategies. Pazopanib is an oral multi-targeted tyrosine kinase inhibitor that is active against advanced soft tissue sarcoma. However, the clinical activity and feasibility of pazopanib for treating Ewing sarcoma remain poorly understood. Moreover, clinical information on the use of tandem high-dose chemotherapy for Ewing sarcoma is limited. A 14-year-old boy with Ewing sarcoma was transferred to our hospital for treatment. Magnetic resonance imaging, computed tomography scans, and bone scintigraphy revealed multiple lesions in the pubis, ilium, ischium, femur, rib, cranial bone, thoracic vertebrae, sacrum, obturator muscle, adductor magnus muscle, testicular cord, and lungs. Bone scintigraphy after intensive chemotherapies confirmed that multiple abnormal accumulations were still present in the cranial bone and pubis. Subsequently, the patient received tandem high-dose chemotherapy including topotecan, and radiotherapy. Abnormal accumulations have disappeared in bone scintigraphy. Subsequently, pazopanib maintenance therapy was initiated. Despite the presence of innumerable lesions at diagnosis, the patient has been in near-complete remission for the past 1 year with pazopanib administration. This confirms that adding pazopanib maintenance therapy after tandem high-dose chemotherapy is a therapeutic option for cases with disseminated Ewing sarcoma.

  Jul. 2019, International cancer conference journal, 8(3) (3), 95 - 100, English, International magazine

  [Refereed]


• 医療技術等国際展開推進事業の取り組み(後編) インドネシアにおける小児がん診療の現状と課題

  山本 暢之, 西村 範行

  産業開発機構(株), May 2019, 映像情報Medical, 51(5) (5), 62 - 65, Japanese


• 医療技術等国際展開推進事業の取り組み(前編) 開発途上国における小児がんの診療能力強化 国際的に注目されつつある課題である小児がんへの対応に関する研修

  七野 浩之, 吉本 優里, 山中 純子, 瓜生 英子, 田中 瑞恵, 佐藤 典子, 加藤 元博, 寺島 慶太, 富澤 大輔, 松井 基浩, 文野 誠久, 菱木 知郎, 土井 崇, 谷ヶ崎 博, 副島 俊典, 浅妻 伴, 大野 孝, 野澤 久美子, 宮崎 治, 山本 暢之, 長谷川 大一郎, 西村 範行, 前田 美穂, 義岡 孝子, 堤 義之, 米田 光宏, 松本 公一

  産業開発機構(株), Apr. 2019, 映像情報Medical, 51(4) (4), 42 - 48, Japanese


• Dynamics of Minimal Residual Disease in Neuroblastoma Patients.

  Suguru Uemura, Toshiaki Ishida, Khin Kyae Mon Thwin, Nobuyuki Yamamoto, Akihiro Tamura, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Kyaw San Lin, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Noriyuki Nishimura

  Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT) and generate diverse cell-types and tissues. Patients with neuroblastoma are characterized by their extreme heterogeneity ranging from spontaneous regression to malignant progression. More than half of newly diagnosed patients present highly metastatic tumors and are stratified into a high-risk group with dismal outcome. As many as 20% of high-risk patients have residual disease that is refractory or progressive during induction chemotherapy. Although a majority of high-risk patients achieve remission, larger part of those patients has minimal residual disease (MRD) that causes relapse even after additional consolidation therapy. MRD is composed of drug-resistant tumor cells and dynamically presented as cancer stem cells (CSCs) in residual tumors, circulating tumor cells (CTCs) in peripheral blood (PB), and disseminated tumor cells (DTCs) in bone marrow (BM) and other metastatic sites. EMT appears to be a key mechanism for cancer cells to acquire MRD phenotypes and malignant aggressiveness. Due to the restricted availability of residual tumors, PB and BM have been used to isolate and analyze CTCs and DTCs to evaluate MRD in cancer patients. In addition, recent technical advances make it possible to use circulating tumor DNA (ctDNA) shed from tumor cells into PB for MRD evaluation. Because MRD can be detected by tumor-specific antigens, genetic or epigenetic changes, and mRNAs, numerous assays using different methods and samples have been reported to detect MRD in cancer patients. In contrast to the tumor-specific gene-rearrangement-positive acute lymphoblastic leukemia (ALL) and the oncogenic fusion-gene-positive chronic myelogenous leukemia (CML) and several solid tumors, the clinical significance of MRD remains to be established in neuroblastoma. Given the extreme heterogeneity of neuroblastoma, dynamics of MRD in neuroblastoma patients will hold a key to the clinical validation. In this review, we summarize the biology and detection methods of cancer MRD in general and evaluate the available assays and clinical significance of neuroblastoma MRD to clarify its dynamics in neuroblastoma patients.

  2019, Frontiers in oncology, 9, 455 - 455, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Clinical Characteristics of Neuroblastoma with Central Nervous System Metastases at First Relapse

  Toshiaki Ishida, Takayuki Ichikawa, Naoko Nakatani, Nanako Nino, Sayaka Nakamura, Nobuyuki Yamamoto, Akihiro Tamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Makiko Yoshida, Atsufumi Kawamura, Yoshinobu Akasaka, Toshinori Soejima, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S39 - S40, English

  [Refereed]


• Re-Considering Old Strategies as Palliative Treatment for DIPG (Diffuse Intrinsic Pontine Glioma)

  Atsufumi Kawamura, Akihiro Tamura, Nobuyuki Yamamoto, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka, Toshinori Soejima

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S77 - S77, English

  [Refereed]


• Successful Induction Therapy with Prednisolone and Maintenance Therapy with Cyclosporine for Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Case Report

  Natsumi Kikuchi, Kenji Kishimoto, Sayaka Nakamura, Takayuki Ichikawa, Naoko Nakatani, Nanako Nino, Akihiro Tamura, Nobuyuki Yamamoto, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S99 - S99, English

  [Refereed]


• Secondary Thyroid Carcinoma After Irradiation for Hematopoietic Stem Cell Transplantation in Childhood

  Aiko Kozaki, Takayuki Ichikawa, Naoko Nakatani, Nanako Nino, Sayaka Nakamura, Akihiro Tamura, Nobuyuki Yamamoto, Atsuro Saito, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S103 - S104, English

  [Refereed]


• Clinical Characteristics and Risk Factors of Hypertension in the Early Phase After Allogeneic Stem Cell Transplantation

  Sayaka Nakamura, Kenji Kishimoto, Takayuki Ichikawa, Naoko Nakatani, Nanako Nino, Akihiro Tamura, Nobuyuki Yamamoto, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S60 - S60, English

  [Refereed]


• Dermal Mucormycosis with Blood Stream Infection During High-Dose Chemotherapy (HDC) with BCOR-ITD Positive Undifferentiated Sarcoma: A Case Report

  Naoko Nakatani, Atsuro Saito, Yusuke Ito, Masashi Kasai, Takayuki Ichikawa, Nanako Nino, Sayaka Nakamura, Nobuyuki Yamamoto, Akihiro Tamura, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S102 - S102, English

  [Refereed]


• Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma

  Akihiro Tamura, Makiko Yoshida, Nobuyuki Yamamoto, Nanako Nino, Naoko Nakatani, Takayuki Ichikawa, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  0

  AMER SOC HEMATOLOGY, Nov. 2018, BLOOD, 132, English

  [Refereed]


• Mediastinal Yolk Sac Tumor in a Patient with Concurrent 8p23.1 Duplication and 8p23.2-pter Deletion

  Nobuyuki Yamamoto, Akihiro Tamura, Keiichi Morita, Hironori Matsuhisa, Naoya Morisada, Naoko Nakatani, Takayuki Ichikawa, Nanako Nino, Sayaka Nakamura, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S50 - S51, English

  [Refereed]


• Spontaneous Development of Spindle Cell Sarcoma in mdx Mice

  Takafuji Satoru, Niba Emma, Khin Thwin, Yamamoto Nobuyuki, Awano Hiroyuki, Uemura Suguru, Mori Takeshi, Fukushima Shoji, Itoh Kyoko, Nishio Hisahide, Matsuo Masafumi, Iijima Kazumoto, Nishimura Noriyuki

  Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S95

  [Refereed]


• Successful Combination Therapy of Liposomal Amphotericin B and Caspofungin for Disseminated Fusariosis in a Pediatric Patient With Acute Lymphoblastic Leukemia.

  Suguru Uemura, Akihiro Tamura, Nobuyuki Yamamoto, Atsuro Saito, Sayaka Nakamura, Takahiro Fujiwara, Teppei Tahara, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Yasunori Muraosa, Katsuhiko Kamei, Yoshiyuki Kosaka

  Disseminated fusariosis is a fatal infection in immunocompromised hosts. However, the optimal antifungal treatment for disseminated fusariosis has not yet been established. We report a case of disseminated fusariosis after chemotherapy for acute lymphoblastic leukemia, presenting with multiple skin, lung and kidney lesions and cerebrospinal fluid invasion. The combination therapy of liposomal amphotericin B and caspofungin resolved disseminated fusariosis successfully.

  Oct. 2018, The Pediatric infectious disease journal, 37(10) (10), e251-e253, English, International magazine

  [Refereed]

  Scientific journal


• Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.

  Akihiro Tamura, Toshiaki Ishida, Atsuro Saito, Nobuyuki Yamamoto, Takehito Yokoi, Suguru Uemura, Nanako Nino, Takahiro Fujiwara, Teppei Tahara, Sayaka Nakamura, Aiko Kozaki, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka

  The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics. Our encouraging data warrant larger prospective studies to assess the efficacy and safety of low-dose AZA maintenance therapy post HSCT for pediatric patients with high-risk AML.

  Oct. 2018, Pediatric blood & cancer, 65(10) (10), e27284, English, International magazine

  [Refereed]

  Scientific journal


• 経時的なRT-qPCRにより、急性GVHD出現後に初めてMRDの消失を確認したNUP98-NSD1陽性AML例(Monitoring RT-qPCR revealed the elimination of MRD after the onset of aGVHD in the NUP98-NSD1(+) AML)

  山本 暢之, 田村 彰広, 長谷川 大一郎, 松井 啓治, 松本 久幸, 中町 祐司, 中谷 尚子, 市川 貴之, 二野 菜々子, 中村 さやか, 藤原 隆弘, 太原 鉄平, 神前 愛子, 齋藤 敦郎, 岸本 健治, 石田 敏章, 三枝 淳, 西村 範行, 小阪 嘉之

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1698 - 1698, English


• デジタルPCRによる高リスク神経芽腫患者の微小残存病変(MRD)の検出(Detection of minimal residual disease in high-risk neuroblastoma patients by digital PCR)

  西村 範行, 石田 敏章, 植村 優, 山本 暢之, 長谷川 大一郎

  日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回, 2012 - 2012, English


• ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.

  Suguru Uemura, Noriyuki Nishimura, Daiichiro Hasegawa, Akemi Shono, Kimiyoshi Sakaguchi, Hisayuki Matsumoto, Yuji Nakamachi, Jun Saegusa, Takehito Yokoi, Teppei Tahara, Akihiro Tamura, Nobuyuki Yamamoto, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Nanako Nino, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Yoshiyuki Kosaka

  ETV6-ABL1 fusion is a rare but recurrent oncogenic lesion found in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), without an established chromosomal abnormality, and is associated with poor outcome. In ETV6-ABL1-positive cases, an in-frame fusion produced by a complex rearrangement results in constitutive chimeric tyrosine kinase activity. Monosomy 7 is also a rare and unfavorable chromosomal abnormality in childhood BCP-ALL. Here, we report a 14-year-old female BCP-ALL patient with ETV6-ABL1 fusion combined with monosomy 7. She was admitted to our hospital because of persistent fever. Bone marrow nuclear cell count on admission was 855,000/µL with 90.0% blastic cells of lymphoid morphology. Blasts were positive for CD10, CD19, CD20, CD34, cyCD79a, cyTdT, HLA-DR, and CD66c, had a karyotype of 45, XX, - 7 [18/20] and a split signal for ABL1 FISH probe (92.7%), and were sensitive to tyrosine kinase inhibitors, imatinib and dasatinib, in vitro. ETV6-ABL1 fusion transcript was identified by whole transcriptome sequencing and confirmed by RT-PCR. She was treated with the high-risk protocol based on ALL-BFM 95, achieved complete remission (CR) after induction chemotherapy, and maintained CR for 4 months. To our knowledge, this is the first report of ETV6-ABL1 fusion combined with monosomy 7 in childhood BCP-ALL.

  May 2018, International journal of hematology, 107(5) (5), 604 - 609, English, Domestic magazine

  [Refereed]

  Scientific journal


• Hematopoietic cell transplantation for asymptomatic X-linked lymphoproliferative syndrome type 1.

  Akihiro Tamura, Suguru Uemura, Nobuyuki Yamamoto, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa, Haruka Hiroki, Tsubasa Okano, Kohsuke Imai, Tomohiro Morio, Hirokazu Kanegane, Yoshiyuki Kosaka

  Background: X-linked lymphoproliferative disease type 1 (XLP1) is a rare primary immune deficiency, which is caused by SH2D1A gene mutations. XLP1 is commonly associated with Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis, hypogammaglobulinemia, and/or lymphoma. The only curative treatment for XLP1 is allogeneic hematopoietic cell transplantation. However, published data detailing the clinical course of, and indications for, allogeneic hematopoietic cell transplantation in asymptomatic patients with XLP1 is lacking. Although relevant family history could be useful in identifying patients with XLP1 before disease onset, no guidelines have been established on the management of asymptomatic patients with XLP1. Therefore, clinicians and families face dilemmas in balancing between the risk of waiting for the disease onset, and the risk of transplant-related mortality associated with allogeneic hematopoietic cell transplantation, which is often performed at a very young age. We first describe the detailed clinical course of an asymptomatic patient with XLP1 who successfully underwent allogeneic hematopoietic cell transplantation. Case presentation: A boy was born at 39 weeks of gestation, weighing 3016 g at birth. He appeared fine, but he underwent genetic testing because his maternal cousin had XLP1. He was found to have a novel c.207_208insC (p.Pro70ProfsX4) mutation in exon 3 of SH2D1A, which was also found in his cousin. There was no HLA-identical donor in his family. Immunoglobulin was administered monthly to prevent EBV infection while searching for an alternative donor. He underwent allogeneic bone marrow transplantation (BMT) from an allele HLA 8/8 fully matched, unrelated donor with a reduced-intensity conditioning (RIC) regimen consisting of fludarabine, melphalan, and low-dose total body irradiation (TBI) at 20 months of age. The patient has been doing well for 2 years post transplantation and maintaining complete donor chimerism without any evidence of chronic graft versus host disease. Conclusions: We describe a case of an asymptomatic patient with XLP1, who successfully underwent unrelated BMT with RIC regimen consisting of fludarabine, melphalan, and 3 Gy TBI. That was well tolerated and successfully generated complete chimerism in every subpopulation. This case delineates the option of allogeneic hematopoietic cell transplantation even in asymptomatic patients with XLP1.

  2018, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14, 82 - 82, English, International magazine

  [Refereed]

  Link to Kobe Univ. Repository (Kernel)


• Molecular Diagnosis of Hemophilia B Leyden in Japanese Brothers Reveals Spontaneous Amelioration in Early Childhood with c.-35 G > A Onecut Binding Site Mutation

  Akihiro Tamura, Daiichiro Hasegawa, Sayaka Nakamura, Takahiro Fujiwara, Teppei Tahara, Nobuyuki Yamamoto, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Keiko Shinozawa, Kagehiro Amano, Katsuyuki Fukutake, Yoshiyuki Kosaka

  0

  AMER SOC HEMATOLOGY, Dec. 2017, BLOOD, 130, English

  [Refereed]


• Treatment Results and Prognostic Factors of Retinoblastoma: A Single Institution Experience

  Takahiro Fujiwara, Atsuro Saito, Sayaka Nakamura, Teppei Tahara, Akihiro Tamura, Nobuyuki Yamamoto, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Daiihiro Hasegawa, Suiho Yanagisawa, Koji Nomura, Yoshiyuki Kosaka

  WILEY, Nov. 2017, PEDIATRIC BLOOD & CANCER, 64, S39 - S40, English

  [Refereed]


• Pathological Fracture in Children with Nonosteogenic Malignant Tumor

  Sayaka Nakamura, Kenji Kishimoto, Takahiro Fujiwara, Teppei Tahara, Nobuyuki Yamamoto, Akihiro Tamura, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2017, PEDIATRIC BLOOD & CANCER, 64, S107 - S107, English

  [Refereed]


• Epidemiology of Factor VIII Inhibitor Development in Patients with Severe Hemophilia A Treated in our Institution

  Teppei Tahara, Toshiaki Ishida, Sayaka Nakamura, Takahiro Fujiwara, Akihiro Tamura, Nobuyuki Yamamoto, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka

  WILEY, Nov. 2017, PEDIATRIC BLOOD & CANCER, 64, S115 - S115, English

  [Refereed]


• Refractory double-hit lymphoma/leukemia in childhood mimicking B-precursor acute lymphoblastic leukemia at initial presentation.

  Suguru Uemura, Daiichiro Hasegawa, Takehito Yokoi, Nanako Nino, Teppei Tahara, Akihiro Tamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Keiichiro Kawasaki, Nobuyuki Yamamoto, Takeshi Mori, Noriyuki Nishimura, Yoshiyuki Kosaka

  A 10-year-old girl was referred to our hospital with left preauricular adenopathy and gingival swelling. She was diagnosed with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) based on being positive for expressions of CD10, CD19, TdT and HLA-DR. She showed no CD20 expression at the time of diagnosis. Based on the initial diagnosis of BCP-ALL, induction chemotherapy for BCP-ALL was initiated. However, the blasts did not disappear from her peripheral blood. Bone marrow examination on day 33 identified 81.3% residual blasts with positive expressions of CD19, 20 and HLA-DR and negative CD10 and TdT expressions; these cells were morphologically and phenotypically different from those at the initial diagnosis. Based on cytogenetic studies, the final diagnosis was double-hit lymphoma/leukemia (DHL) with IgH-BCL2 and Igλ-MYC. Although dose intensive chemotherapy, including rituximab, led to complete remission, bone marrow and central nervous system relapse occurred. At relapse, blasts expressed CD10, CD19 and HLA-DR, but not CD20, findings the same as those at the onset. The patient died of the disease 44 days after cord blood transplantation with non-remission status. DHL in childhood is extremely rare and its prognosis is poor. The establishment of an effective treatment for DHL is highly anticipated.

  (一社)日本血液学会-東京事務局, 2017, [Rinsho ketsueki] The Japanese journal of clinical hematology, 58(2) (2), 143 - 149, Japanese, Domestic magazine

  [Refereed]

  Scientific journal


• Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.

  Satoshi Hirase, Atsuro Saitoh, Tri Budi Hartomo, Aiko Kozaki, Tomoko Yanai, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Nobuyuki Yamamoto, Takeshi Mori, Akira Hayakawa, Kazumoto Iijima, Hisahide Nishio, Noriyuki Nishimura

  Neuroblastoma is an aggressive pediatric tumor accounting for ~15% of cancer-associated mortalities in children. Despite the current intensive therapy, >50% of high-risk patients experience tumor relapse or regrowth caused by the activation of minimal residual disease (MRD). Although several MRD detection protocols using various reverse transcription-quantitative polymerase chain reaction (RT-qPCR) markers have been reported to evaluate the therapeutic response and disease status of neuroblastoma patients, their clinical significance remains elusive. The present study reports two high-risk neuroblastoma patients, whose MRD was consecutively monitored using 11 RT-qPCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) during their course of treatment. The two patients initially responded to the induction therapy and reached MRD-negative status. The patients' MRD subsequently became positive with no elevation of their urinary homovanillic acid, urinary vanillylmandelic acid and serum neuron-specific enolase levels at 13 or 19 weeks prior to the clinical diagnosis of tumor relapse or regrowth. The present cases highlight the possibility of consecutive MRD monitoring using 11 markers to enable an early detection of tumor relapse or regrowth in high-risk neuroblastoma patients.

  Aug. 2016, Oncology letters, 12(2) (2), 1119 - 1123, English, International magazine

  [Refereed]

  Scientific journal


• Transient hyperphosphatasemia in three pediatric patients treated with cyclosporine.

  Takeshi Mori, Ryojiro Tanaka, Kosuke Nishida, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Kandai Nozu, Kazumoto Iijima

  Transient hyperphosphatasemia (TH) is defined as marked elevation of serum alkaline phosphatase (ALP), predominantly its bone or liver isoform. It is a rare condition and is usually detected on laboratory examination in patients without any clinical symptoms. In typical patients with TH, ALP spontaneously normalizes, but no apparent cause of TH has been identified. Some drugs are suspected triggers of TH, but no clear evidence of their association with TH has been shown to date. We herein report three cases of TH in pediatric patients. Two patients were treated with cyclosporine for frequently relapsing nephrotic syndrome, and one was also taking cyclosporine for aplastic anemia. Interestingly, ALP immediately decreased after termination of cyclosporine in two patients, whereas TH lasted 4 months in the one patient who continued cyclosporine. Clearly, cyclosporine is associated with the pathophysiology of TH in children.

  WILEY-BLACKWELL, May 2016, Pediatrics international : official journal of the Japan Pediatric Society, 58(5) (5), 429 - 30, English, International magazine

  [Refereed]

  Scientific journal


• 神経芽腫患者の微小残存病変モニタリング

  西村 範行, トゥインキン・キモン, 山本 暢之, 森 健, 早川 晶, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, 西尾 久英, 飯島 一誠

  (公社)日本小児科学会, Feb. 2016, 日本小児科学会雑誌, 120(2) (2), 316 - 316, Japanese


• Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

  Nobuyuki Yamamoto, Aiko Kozaki, Tri Budi Hartomo, Tomoko Yanai, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Satoshi Hirase, Takeshi Mori, Akira Hayakawa, Kazumoto Iijima, Hisahide Nishio, Noriyuki Nishimura

  Neuroblastoma is an aggressive solid tumor that leads to tumor relapse in more than half of high-risk patients. Minimal residual disease (MRD) is primarily responsible for tumor relapses and may be detected in peripheral blood (PB) and bone marrow (BM) samples. To evaluate the disease status and treatment response, a number of MRD detection protocols based on either common or distinct markers for PB and BM samples have been reported. However, the correlation between the expression of MRD markers in PB and BM samples remains elusive in the clinical samples. In the present study, the expression of 11 previously validated MRD markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) was determined in 23 pairs of PB and BM samples collected from seven high-risk neuroblastoma patients at the same time point, and the sample was scored as MRD-positive if one of the MRD markers exceeded the normal range. Although the number of MRD-positive samples was not significantly different between PB and BM samples, the two most sensitive markers for PB samples (CRMP1 and KIF1A) were different from those for BM samples (PHOX2B and DBH). There was no statistically significant correlation between the expression of MRD markers in the PB and BM samples. These results suggest that MRD markers were differentially expressed in PB and BM samples from high-risk neuroblastoma patients.

  SPANDIDOS PUBL LTD, Nov. 2015, Oncology letters, 10(5) (5), 3228 - 3232, English, International magazine

  [Refereed]

  Scientific journal


• Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia.

  Satoshi Hirase, Daiichiro Hasegawa, Hironobu Takahashi, Kensuke Moriwaki, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Tomoko Yanai, Keiichiro Kawasaki, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Akira Hayakawa, Noriyuki Nishimura, Hisahide Nishio, Kazumoto Iijima, Yoshiyuki Kosaka

  Recent studies have reported that the absolute lymphocyte count (ALC) during induction therapy is predictive of treatment outcome in de novo acute lymphoblastic leukemia (ALL); however, the significance of ALC on outcomes remains controversial. In the present study, we assessed the significance of ALC at day 29 (ALC-29), the end of induction therapy, on outcomes in our Japanese cohort. The outcomes of 141 patients aged ≤18 years with newly diagnosed ALL who were enrolled on the JACLS ALL-02 at our hospitals were analyzed in terms of ALC-29. Patients with ALC-29 ≥750/μL (n = 81) had a superior 5-year EFS (95.2 ± 2.7 vs 84.3 ± 4.8 %, P = 0.016) and OS (100 vs 87.0 ± 4.7 %, P = 0.0062). A multivariate analysis identified ALC-29 ≥750/μL as a significant predictor of improved EFS and OS after controlling for confounding factors. A multiple linear regression model revealed a significant inverse relationship between the percentage of blasts in bone marrow on day 15 and ALC-29 (P = 0.005). These results indicate that ALC is a simple prognostic factor in childhood ALL, and, thus, has the potential to refine current risk algorithms.

  SPRINGER JAPAN KK, Nov. 2015, International journal of hematology, 102(5) (5), 594 - 601, English, Domestic magazine

  [Refereed]

  Scientific journal


• DENNドメイン蛋白質DENND2Aによる神経芽腫の制御機構(DENN domain protein DENND2A mediates the progression of neuroblastoma)

  山本 暢之, 堀之内 智子, 藤村 順也, 森 健, 早川 晶, 長谷川 大一郎, 小阪 嘉之, 西尾 久英, 飯島 一誠, 西村 範行

  (一社)日本小児血液・がん学会, Oct. 2015, 日本小児血液・がん学会雑誌, 52(4) (4), 257 - 257, English


• 高リスク神経芽腫患者の骨髄と末梢血における微小残存病変の発現についての検討(Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients)

  植村 優, 山本 暢之, 神前 愛子, 二野 菜々子, 高藤 哲, 横井 健人, 齋藤 敦郎, 石田 敏章, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, 平瀬 聡史, 森 健, 早川 晶, 飯島 一誠, 西尾 久英, 西村 範行

  (一社)日本小児血液・がん学会, Oct. 2015, 日本小児血液・がん学会雑誌, 52(4) (4), 257 - 257, English


• 海綿状血管腫と鑑別を要した右下腿原発乳児線維肉腫

  久保川育子, Hayakawa Akira, 西田浩輔, 平瀬敏志, 山本暢之, 森健, 徳田央士, 上田雅章, Iijima Kazumoto

  日齢11、男児。出生時より右下腿に鶏卵大の腫瘤を認め、海綿状血管腫が疑われ、経過観察していた。その後増大傾向を認め、β遮断薬の治療目的に日齢11に当科入院となった。右下腿に手拳大の赤紫色で弾性硬な腫瘤を認め、腫瘤周囲径は22.3cm、足関節周囲径は9cmに増大し、可動性が不良であった。その後も腫瘤増大が急速であったため、海綿状血管腫や乳児血管腫を疑い、生検を施行した。β遮断薬内服を開始したが無効であり、腫瘤は日毎に増大し、日齢17にMRIにて100×82×80mmの巨大な腫瘤を認めた。また、高Ca血症の進行も認めたため、右股関節離断術を施行した。摘出した腫瘍は腓骨の近位部まで浸食していた。腫瘍組織のRT-PCRにてETS variant gene 6;neutrophic tyrosine kinase receptor type 3融合遺伝子を検出し、乳児線維肉腫と診断した。高Ca血症の原因は腫瘍によるホルモン産生性高Ca血症と判明した。術後は血清Ca値は速やかに正常化し、全身状態も良好となり、日齢43に退院となった。

  (公社)日本小児科学会, Sep. 2015, 日本小児科学会雑誌, 119(9) (9), 1374 - 1379, Japanese


• Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma.

  Tri Budi Hartomo, Thi Van Huyen Pham, Nobuyuki Yamamoto, Satoshi Hirase, Daiichiro Hasegawa, Yoshiyuki Kosaka, Masafumi Matsuo, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Hisahide Nishio, Noriyuki Nishimura

  Despite the introduction of 13-cis-retinoic acid (13-cis-RA) into the current chemotherapy, more than half of high-risk neuroblastoma patients have experienced tumor relapses driven by chemoresistant cancer stem cells (CSCs) that can be isolated by their ability to grow as spheres. Although aldehyde dehydrogenase (ALDH) has been used to characterize CSCs in certain cancers, ALDH remains elusive in neuroblastoma. In the present study, we determined ALDH activity and expression of its 19 isoforms in spheres and parental cells of neuroblastoma. ALDH activity and several ALDH isoforms were consistently induced in spheres of different neuroblastoma cells. While ALDH1A2, ALDH1L1 and ALDH3B2 expression was consistently induced in spheres and associated with the sphere and colony formation, only ALDH1A2 expression was significantly correlated with the poor prognosis of neuroblastoma patients. ALDH1A2 expression was further associated with the growth and undifferentiation of neuroblastoma xenografts and the resistance of neuroblastoma cells to 13-cis-RA. These results suggest that ALDH1A2 is involved in the regulation of CSC properties in neuroblastoma.

  SPANDIDOS PUBL LTD, Mar. 2015, International journal of oncology, 46(3) (3), 1089 - 98, English, International magazine

  [Refereed]

  Scientific journal


• The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.

  Nobuyuki Yamamoto, Noriyuki Nishimura, Mai Takeuchi, Tomoo Ito, Hiroshi Yokozaki, Satoshi Hirase, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Hisahide Nishio, Masafumi Matsuo, Ken-Ichi Imadome, Kazumoto Iijima

  Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized aggressive disease commonly associated with Epstein-Barr virus (EBV) infection after hematopoietic stem cell transplantation (HSCT). Although rituximab (RTX) is incorporated into the first-line therapy for EBV-PTLD patients, the outcome of the clinically overt disease is still not optimal mainly due to the regrowth of tumor cells. The proliferation of CD20-/CD19+ tumor cells is increasingly reported in RTX-treated EBV-PTLD patients, whereas the emergence of CD20-/CD19- tumor cells is barely recognized. Here, we report a fatal case of an 18-year-old patient who developed EBV-PTLD after allogeneic HSCT for anaplastic large-cell lymphoma. On day 60 after HSCT, the patient developed abdominal pain, watery diarrhea, and low-grade fever. Colon biopsy revealed the proliferation of CD20+/CD19+/EBV-encoded RNA (EBER)+ tumor cells, and an increase of EBV DNA was detected in peripheral blood (PB). He was treated with RTX for EBV-PTLD and was cleared of EBV DNA in PB. However, he manifested high-grade fever, pancytopenia, and elevated soluble interleukin-2 receptor with a prominent hemophagocytosis in bone marrow aspirates and was treated with etoposide for hemophagocytic lymphohistiocytosis (HLH) complication. He then developed EBV DNA positivity in PB and finally died of Bacteroides fragilis sepsis subsequent to bloody stool and ileus on day 163. Autopsy revealed erosion and bleeding in the whole colon with the proliferation of CD20-/CD19-/EBER+ tumor cells. Immunohistochemical analysis uncovered the CD3-/CD56-/CD79a+/CD79b+ B-cell origin of tumor cells. This case clinically demonstrates the removal of both CD20 and CD19 antigens from EBER+ B cells in an RTX-treated EBV-PTLD patient with HLH complication.

  SPRINGER, Dec. 2014, European journal of pediatrics, 173(12) (12), 1615 - 8, English, International magazine

  [Refereed]

  Scientific journal


• The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.

  Ikuko Kubokawa, Akihiro Yachie, Akira Hayakawa, Satoshi Hirase, Nobuyuki Yamamoto, Takeshi Mori, Tomoko Yanai, Yasuhiro Takeshima, Eiryu Kyo, Goichi Kageyama, Hiroshi Nagai, Keiichiro Uehara, Masaru Kojima, Kazumoto Iijima

  BACKGROUND: TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan. It is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, reticulin Fibrosis of the bone marrow, Renal dysfunction and Organomegaly (TAFRO). Previous reports have shown that affected patients usually respond to immunosuppressive therapy, but the disease sometimes has a fatal course. TAFRO syndrome occurs in the middle-aged and elderly and there are no prior reports of the disease in adolescents. Here we report the first adolescent case, successfully treated with anti-IL-6 receptor antibody (tocilizumab, TCZ) and monitored with serial cytokine profiles. CASE PRESENTATION: A 15-year-old Japanese boy was referred to us with fever of unknown origin. Whole body computed tomography demonstrated systemic lymphadenopathy, organomegaly and anasarca. Laboratory tests showed elevated C-reactive protein and hypoproteinemia. Bone marrow biopsy revealed a hyperplastic marrow with megakaryocytic hyperplasia and mild reticulin fibrosis. Despite methylprednisolone pulse therapy, the disease progressed markedly to respiratory distress, acute renal failure, anemia and thrombocytopenia. Serum and plasma levels of cytokines, including IL-6, vascular endothelial growth factor, neopterin and soluble tumor necrosis factor receptors I and II, were markedly elevated. Repeated weekly TCZ administration dramatically improved the patient's symptoms and laboratory tests showed decreasing cytokine levels. CONCLUSION: To our knowledge, this is the first report of TAFRO syndrome in a young patient, suggesting that this disease can occur even in adolescence. The patient was successfully treated with TCZ. During our patient's clinical course, monitoring cytokine profiles was useful to assess the disease activity of TAFRO syndrome.

  BIOMED CENTRAL LTD, Jun. 2014, BMC pediatrics, 14, 139 - 139, English, International magazine

  [Refereed]

  Scientific journal


• メソトレキセート大量療法後の急性腎不全に対し血液浄化療法を施行した若年成人急性リンパ性白血病の1例

  Hayakawa Akira

  (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2013, 日本小児血液・がん学会学術集会,日本小児がん看護学会,公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号55回・11回・18回, 55回・11回・18回, 338 - 338, Japanese


• 初診時に血管腫と鑑別を要した右下腿原発乳児線維肉腫の新生児例

  久保川 育子, 西田 浩輔, 平瀬 敏志, 山本 暢之, 森 健, Hayakawa Akira, 江尻 浩隆, 西井 達也, 藤原 周一, 大西 康央, 原 仁美, Kawamoto Teruya, Akisue Toshihiro, 大谷 恭子, 酒井 康裕, Hara Shigeo, 廣瀬 隆則, 伊藤 智雄, 大喜多 肇, 飯島 一誠

  (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2013, 日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号55回・11回・18回, 55回・11回・18回, 275 - 275, Japanese


• 大量化学療法後早期に再発し終末期を迎えたユーイング肉腫の青年期男性例 終末期の予後告知をめぐる本人・家族との関わりについて

  山本 暢之, 平瀬 敏志, 松野下 夏樹, 森 健, 矢内 友子, Hayakawa Akira, 飯島 一誠, 石橋 有希, 太田垣 加奈子, 渡辺 元雄, Sakashita Akihiro

  (一社)日本小児血液・がん学会, Oct. 2013, 日本小児血液・がん学会雑誌, 50(3) (3), 489 - 489, Japanese


• Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.

  Tri Budi Hartomo, Aiko Kozaki, Daiichiro Hasegawa, Thi Van Huyen Pham, Nobuyuki Yamamoto, Atsuro Saitoh, Toshiaki Ishida, Keiichiro Kawasaki, Yoshiyuki Kosaka, Hiroki Ohashi, Tomoto Yamamoto, Satoru Morikawa, Satoshi Hirase, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Masafumi Matsuo, Hisahide Nishio, Noriyuki Nishimura

  Minimal residual disease (MRD) is derived from tumor-initiating cells (TICs) and is responsible for tumor relapse. Neuroblastoma is characterized by extreme tumor heterogeneity, and more than half of high-risk patients experience tumor relapse. To overcome tumor heterogeneity and achieve more sensitive detection of MRD, several sets of real-time RT-PCR markers have been reported for MRD monitoring in neuroblastoma patients from different centers. However, these markers vary across centers and are still being validated. In the present study, we validated the ability of 14 commonly used real-time RT-PCR markers to detect MRD based on their expression in neuroblastoma TICs, and we developed a novel MRD detection protocol, which scored the samples as MRD-positive when the expression of one of the 11 real-time RT-PCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) exceeded the normal range. By using this protocol, we prospectively monitored MRD in 73 bone marrow (BM), 12 peripheral blood stem cell and 8 peripheral blood samples from 14 neuroblastoma patients treated at a single center. We scored 100, 56, 56 and 57% BM cytology-positive, elevated vanillylmandelic acid (VMA), elevated homovanillic acid (HVA) and elevated neuron-specific enolase (NSE) samples as MRD-positive, respectively. MRD was also positive in 48, 45, 46 and 43% of the BM cytology-negative and normal VMA, normal HVA and normal NSE samples, respectively. These results suggest that the present MRD detection protocol based on the expression of a set of 11 real-time RT-PCR markers in neuroblastoma TICs achieves sensitive MRD monitoring in neuroblastoma patients.

  Apr. 2013, Oncology reports, 29(4) (4), 1629 - 36, English, International magazine

  [Refereed]

  Scientific journal


• 初診時、播種性血管内凝固(DIC)を合併、急性白血病が疑われた胞巣型横紋筋肉腫の一症例

  岡崎 葉子, 早川 晶, 森 健, 山本 暢之, 菊間 知恵, 東口 佳苗, 川上 史, 林 祥剛, 林 伸英, 河野 誠司

  症例は13歳女児で、白血球数増多と血小板数減少、DICを呈し、末梢血白血球分画にて芽球様細胞が認められたことから急性白血病が疑われた。しかし、骨髄検査では有核細胞数22.1万/μL、N/C比小、核小体明瞭、細胞質辺縁不整で空胞形成があり、集塊状で細胞間の境界が不明瞭な異型細胞を84.6%認めた。細胞表面マーカー解析にてCD45陰性、CD56陽性であったことから、非造血器腫瘍の骨髄浸潤が疑われ、RT-PCR法にてPAX3/FKHRキメラ遺伝子を検出したことから、分子生物学的に胞巣型横紋筋肉腫(ARMS)と診断した。ARMSと診断された時点で全身状態は著しく不良となっており、第16病日に死亡した。

  (一社)日本検査血液学会, Feb. 2013, 日本検査血液学会雑誌, 14(1) (1), 57 - 63, Japanese


• Primary pediatric endobronchial Ewing sarcoma family of tumors.

  Akira Hayakawa, Satoshi Hirase, Natsuki Matsunoshita, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Yoshimasa Maniwa, Kazumoto Iijima

  BACKGROUND: Ewing sarcoma family of tumors is the second most common primary bone tumor of childhood. Extraosseous Ewing sarcoma family of tumors is rare. We present a pediatric case of primary endobronchial Ewing sarcoma family of tumors. CASE REPORT: A 12-year-old boy presented with dyspnea and chest radiography showed right pulmonary atelectasis. Chest computed tomography demonstrated tumor in the right main bronchus. Histopathological examination of the resected tumor demonstrated Ewing sarcoma family of tumors. No other lesions were detected throughout the body and the right main bronchus was thought to be the primary site. As of 1 year and 6 months after further resection of residual tumor followed by chemotherapy and radiotherapy, the patient remains disease-free. CONCLUSIONS: Extraosseous Ewing sarcoma family of tumors arises in soft tissues of the trunk or extremities, but primary endobronchial Ewing sarcoma family of tumors has rarely been reported. Although quite rare, Ewing sarcoma family of tumors should be considered among the differential diagnoses for pediatric bronchial tumor.

  2013, The American journal of case reports, 14, 67 - 9, English, International magazine

  [Refereed]

  Scientific journal


• Place of death of pediatric cancer patients in a single institute during 7 years.

  Tomoko Yanai, Satoshi Hirase, Natsuki Matsunoshita, Nobuyuki Yamamoto, Takeshi Ninchoji, Ikuko Kubokawa, Takeshi Mori, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Masafumi Matsuo

  Place of death is an important issue at the end-of-life. It is poorly understood in pediatric cancer patients in Japan. This study aimed to clarify place of death of children with cancer as well as variables associated with place of death. Study population was pediatric cancer patients who died in the Department of Pediatrics at Kobe University Hospital during the last 7 years. The medical records were retrospectively reviewed regardless of cause of death to derive data relating to patients' characteristics and disease. 18 patients were included. Median age at death was 12.2 years old. 6 patients including 5 children in complete remission had hematological disease and 12 patients suffered from solid tumors. 4 patients (22.2%) died at home, whereas 14 patients (77.8%) died in the hospital including 6 ICU deaths. No one died in hospices. Preference of patients was unavailable due to the lack of inquiry. Factors influencing place of death (home, ICU, non-ICU) were disease (hematological disease vs. solid tumor, p=0.010, brain tumor vs. non-brain tumor, p=0.023), disease status (complete remission vs. non-complete remission, p=0.0014) and preference of families (p=0.029). Among 6 families who expressed preference, no disparity was observed between actual and preferred place of death. This is the first English publication of place of death of pediatric cancer patients in Japan. The low percentage of home death, factors influencing place of death and the lack of disparity between actual and preferred place of death were indicated. Further studies are required to better understand place of death.

  Jun. 2012, The Kobe journal of medical sciences, 58(2) (2), E33-40 - 40, English, Domestic magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rab15 alternative splicing is altered in spheres of neuroblastoma cells.

  Thi Van Huyen Pham, Tri Budi Hartomo, Myeong Jin Lee, Daiichiro Hasegawa, Toshiaki Ishida, Keiichiro Kawasaki, Yoshiyuki Kosaka, Tomoto Yamamoto, Satoru Morikawa, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Masafumi Matsuo, Hisahide Nishio, Noriyuki Nishimura

  Neuroblastoma is an aggressive pediatric tumor that accounts for 15% of cancer-related deaths in children. More than half of high-risk neuroblastoma patients develop tumor relapse that is lethal in most cases. A small population of tumor-initiating cells (TICs), recently identified from high-risk neuroblastoma patients as spheres, is believed to be responsible for tumor relapse. Rab family small G proteins are essential in controlling membrane traffic and their misregulation results in several cancers. Rab15 was originally isolated as a brain-specific Rab protein regulating the endocytic recycling pathway and was recently identified as a downstream target of the neural transcription factor Atoh1. Previously, we identified two alternatively spliced Rab15 isoforms in neuroblastoma cells and showed a significant correlation between Rab15 expression and neuronal differentiation. As aberrant alternative splicing is intimately associated with an increasing number of cancers, its use as a new diagnostic and/or prognostic biomarker has attracted considerable attention. In the present study, we explored cancer-associated changes of Rab15 alternative splicing in neuroblastoma TICs. We found that Rab15 alternative splicing generated two novel isoforms designated as Rab15(AN2) and Rab15(AN3) in addition to two known isoforms designated as Rab15(CN) and Rab15(AN1). Although both Rab15(AN2) and Rab15(AN3) contained premature termination codons, they were detected in not only neuroblastoma cells but also in normal human tissues. One isoform was predominantly expressed in the brain and testis, while the other isoform was more specifically expressed in the brain. In neuroblastoma, Rab15 isoform balance measured by the Rab15(CN)/Rab15(AN1+AN2+AN3) ratio was significantly decreased in spheres compared to parental cells. These results suggest that Rab15 alternative splicing may serve as a biomarker to discriminate TICs from non-TICs in neuroblastoma.

  SPANDIDOS PUBL LTD, Jun. 2012, Oncology reports, 27(6) (6), 2045 - 9, English, International magazine

  [Refereed]

  Scientific journal


• タンデム自家造血細胞移植併用大量化学療法を施行後3年寛解を維持している初診時全身骨髄転移陽性Ewing肉腫ファミリー腫瘍の1例

  Kubokawa Ikuko, Hayakawa Akira, Toyoshima Daisaku, Mitsuda Yoshihiro, Mori Takeshi, Yanai Tomoko, Hara Hitomi, Kawamoto Teruya, Kishimoto Kenta, Akisue Toshihiro, Iijima Kazumoto, Matsuo Masafumi

  症例は12歳男児。左下肢痛を主訴に左距骨腫瘍を疑われ当院紹介となった。初診時、血液検査にて血小板減少、高LDH血症、高尿酸血症、高Ca血症を認めた。骨髄検査にてCD45(-)CD56(+)を示す大型異型細胞を74.4%認め、FDG-PETにて骨髄多発性に異常集積を示し、固形腫瘍の骨髄転移と考えられた。左距骨腫瘍生検にて、Ewing肉腫ファミリー腫瘍(以下、ESFT)と診断し、VDC-IE化学療法を開始した。1コース終了後、骨髄転移は消失し、左距骨原発巣の縮小を認め、5コース終了後にタンデム自家造血細胞移植併用大量化学療法、局所放射線療法を施行した。治療終了後3年経過した現在も無病生存中である。骨髄転移陽性ESFTは極めて予後不良であるが、今回我々は、通常化学療法に良好な反応を示し、タンデム自家造血細胞移植併用大量化学療法後、3年以上の寛解を維持している初診時骨髄転移陽性ESFTの1例を経験した。高リスク群ESFTに対し、タンデム自家造血細胞移植併用大量化学療法は有用な可能性がある。(著者抄録)

  (一社)日本小児血液・がん学会, May 2012, 日本小児血液・がん学会雑誌, 49(1-2) (1-2), 115 - 120, Japanese


• Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.

  Noriyuki Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham, Myeong Jin Lee, Tomoto Yamamoto, Satoru Morikawa, Daiichiro Hasegawa, Hiroki Takeda, Keiichiro Kawasaki, Yoshiyuki Kosaka, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Masafumi Matsuo, Hisahide Nishio

  OBJECTIVES: A growing number of epidemiological studies have demonstrated that the consumption of green tea inhibits the growth of a variety of cancers. Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been shown to have an anti-cancer effect against many cancers. Most cancers are believed to be initiated from and maintained by a small population of tumor-initiating cells (TICs) that are responsible for chemotherapeutic resistance and tumor relapse. In neuroblastoma, an aggressive pediatric tumor that often relapses and has a poor prognosis, TICs were recently identified as spheres grown in a serum-free non-adherent culture used for neural crest stem cell growth. Although EGCG has been reported to induce growth arrest and apoptosis in neuroblastoma cells, its effect on neuroblastoma TICs remains to be defined. METHODS: Gene expression was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR). The effects of EGCG on cell proliferation, apoptosis, and sphere formation were determined by cell counting, propidium iodide staining, and sphere (>100 μm in diameter) counting, respectively. RESULTS: Neuroblastoma BE(2)-C cells showed increased expression of stem cell markers (nanog homeobox [NANOG] and octamer-binding transcription factor 4 [OCT4]), as well as decreased expression of neuronal differentiation markers (Cu(2+)-transporting ATPase alpha polypeptide [ATP7A] and dickkopf homolog 2 [DKK2]) in spheres grown in serum-free non-adherent culture, compared to parental cells grown in conventional culture. Although EGCG induced growth arrest and apoptosis in the parental cells in a dose-dependent manner, it was not effective against spheres. However, EGCG potently inhibited sphere formation in the BE(2)-C cells. CONCLUSIONS: The present results suggest that EGCG may inhibit the development of TICs in BE(2)-C cells.

  May 2012, Environmental health and preventive medicine, 17(3) (3), 246 - 51, English, International magazine

  [Refereed]

  Scientific journal


• Rab15 expression correlates with retinoic acid-induced differentiation of neuroblastoma cells.

  Noriyuki Nishimura, Thi Van Huyen Pham, Tri Budi Hartomo, Myeong Jin Lee, Daiichiro Hasegawa, Hiroki Takeda, Keiichiro Kawasaki, Yoshiyuki Kosaka, Tomoto Yamamoto, Satoru Morikawa, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Hisahide Nishio, Masafumi Matsuo

  Neuroblastoma is the most common extracranial solid tumor in children and accounts for 15% of pediatric cancer deaths. Although retinoic acid (RA) is currently used to treat high-risk neuroblastoma patients in the clinic, RA-responsiveness is variable and unpredictable. Since no alterations in the RA-signaling pathway have been found in neuroblastoma cells, molecules correlated with RA-induced differentiation will provide predictive markers of RA-responsiveness for clinical use. The Rab family of small G proteins are key regulators of membrane traffic and play a critical role in cell differentiation and cancer progression. Although an increasing number of cancer-associated alternative splicing events have been identified, alternative splicing of Rab proteins remains to be characterized in neuroblastoma. In the present study, we focused on Rab15 that was originally identified as a brain-specific Rab protein and regulates the endocytic recycling pathway. We identified alternatively spliced Rab15 isoforms designated as Rab15CN and Rab15AN in neuroblastoma cells. Rab15CN was composed of 7 exons encoding 212 amino acids and showed brain-specific expression. Alternative splicing of exon 4 generated Rab15AN that was predicted to encode 208 amino acids and was predominantly expressed in testis. RA induced neuronal differentiation of neuroblastoma BE(2)-C cells and specifically up-regulated Rab15CN expression. Reciprocally, RA-induced differentiation was observed in Rab15CN-expressing BE(2)-C cells in preference to Rab15AN-expressing BE(2)-C cells. Furthermore, Rab15CN expression was also specifically up-regulated during RA-induced differentiation of newly established neuroblastoma cells from high-risk patients. These results suggest that Rab15 expression correlates with RA-induced differentiation of neuroblastoma cells.

  Jul. 2011, Oncology reports, 26(1) (1), 145 - 51, English, International magazine

  [Refereed]

  Scientific journal

• 副腎皮質腫瘍を合併したBeckwith-Wiedemann症候群の一例

  杉村竜太郎, 西村明紘, 藤川朋子, 井上翔太郎, 田村彰広, 山本暢之, 野津寛大, 尾藤裕子, 大片祐一, 亀岡泰幸

  2024, 近畿小児科学会プログラム・抄録集, 37th


• Bio-absorbable polyglycolic acid spacer placement surgery for malignant abdominal tumor treatment: Clinical observations at Kobe University

  大片祐一, 小松昇平, 出水祐介, 山本暢之, 佐々木良平, 福本巧, 尾藤祐子

  2023, 日本小児血液・がん学会雑誌(Web), 60(5) (5)


• Prognostic Values of Tumor Markers and Minimal Residual Disease Detected by 7NB-mRNAs ddPCR Assay for High-Risk Neuroblastoma Patients

  Suguru Uemura, Toshiaki Ishida, Sanlin Kyaw, Naoko Nakatani, Nanako Nino, Nobuyuki Yamamoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Kazumoto Iijima, Noriyuki Nishimura

  WILEY, Dec. 2020, PEDIATRIC BLOOD & CANCER, 67, English

  Summary international conference


• 再発・増悪した限局性Ewing肉腫ファミリー腫瘍症例の治療成績のまとめ 日本ユーイング肉腫研究グループによる後方視的検討

  梅田 雄嗣, 宮村 能子, 山田 健志, 細野 亜古, 佐野 秀樹, 角 美奈子, 大喜多 肇, 熊本 忠史, 川井 章, 平山 淳也, 上甲 良二, 澤田 明久, 中山 秀樹, 細谷 要介, 前田 尚子, 山本 暢之, 今井 千速, 長谷川 大一郎, 陳 基明, 尾崎 敏文

  (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1453 - S1453, Japanese


• 医療技術等国際展開推進事業 小児がんの診療能力強化(前編) 開発途上国における小児がん診療能力強化事業5年間のまとめ

  七野 浩之, 山中 純子, 鈴木 優里, 瓜生 英子, 加藤 元博, 寺島 慶太, 富沢 大輔, 松本 公一, 副島 俊典, 山本 暢之, 長谷川 大一郎, 西村 範行, 義岡 孝子, 上原 秀一郎, 望月 慎史, 浅妻 伴, 大野 孝, 堤 義之, 菱木 知郎, 米田 光宏

  産業開発機構(株), May 2020, 映像情報Medical, 52(5) (5), 40 - 45, Japanese


• Three Cases of Nasopharyngeal Carcinoma in a Single Institute

  Shotaro Inoue, Suguru Uemura, Nanako Nino, Satoru Takahuji, Nobuyuki Yamamoto, Noriyuki Nishimura, Toshiaki Ishida, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Kazumoto Iijima

  WILEY, Dec. 2019, PEDIATRIC BLOOD & CANCER, 66, S50 - S51, English

  Summary international conference


• Level of Seven Neuroblastoma-Associated mRNAs Analyzed by ddPCR is Correlated Between Bone Marrow and Peripheral Blood in High-risk Neuroblastoma

  Suguru Uemura, Toshiaki Ishida, Kyaemonthwin Khin, Sanlin Kyaw, Nobuyuki Yamamoto, Akihiro Tamura, Atsuro Saito, Kenji Kishimoto, Takeshi Mori, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Satoru Takafuji, Kazumoto Iijima, Noriyuki Nishimura

  WILEY, Dec. 2019, PEDIATRIC BLOOD & CANCER, 66, S81 - S82, English

  Summary international conference


• 血友病未治療例(PUPs)に対する半減期延長凝固因子製剤(EHL)の使用経験

  市川 貴之, 中谷 尚子, 二野 菜々子, 中村 さやか, 山本 暢之, 田村 彰広, 齋藤 敦郎, 神前 愛子, 岸本 健治, 石田 敏章, 長谷川 大一郎, 小阪 嘉之

  (一社)日本小児血液・がん学会, Sep. 2019, 日本小児血液・がん学会雑誌, 56(2) (2), 256 - 257, Japanese


• 集学的治療を行った転移性ユーイング肉腫(ESFT)の2例

  中谷 尚子, 齋藤 敦郎, 市川 貴之, 二野 菜々子, 中村 さやか, 山本 暢之, 田村 彰広, 神前 愛子, 岸本 健治, 石田 敏章, 坂田 亮介, 吉田 牧子, 長谷川 大一郎, 小阪 嘉之

  (一社)日本小児血液・がん学会, Sep. 2019, 日本小児血液・がん学会雑誌, 56(2) (2), 258 - 258, Japanese


• 神経芽腫の七つのmRNA発現に関する骨髄と末梢血サンプルの相関(Expression of seven neuroblastoma-associated mRNAs is correlated between bone marrow and peripheral blood samples)

  Thwin KhinKyaemon, Lin Kyaw San, Ishida Toshiaki, Hasegawa Daiichiro, Uemura Suguru, 山本 暢之, Nishimura Noriyuki

  日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, E - 1060, English


• 治療歴のない血友病患者(PUPs)に対する半減期延長凝固因子製剤(EHL)の使用経験

  長谷川 大一郎, 市川 貴之, 中谷 尚子, 二野 菜々子, 中村 さやか, 山本 暢之, 田村 彰広, 齋藤 敦郎, 神前 愛子, 岸本 健治, 石田 敏章, 小阪 嘉之

  (一社)日本血栓止血学会, May 2019, 日本血栓止血学会誌, 30(2) (2), 450 - 450, Japanese


• 兵庫県がん・生殖医療ネットワークを通じた小児がん患者における卵巣凍結保存の取り組み

  山本 暢之, 脇本 裕, 中谷 尚子, 市川 貴之, 二野 菜々子, 中村 さやか, 田村 彰広, 神前 愛子, 齋藤 敦郎, 岸本 健治, 石田 敏章, 長谷川 大一郎, 柴原 浩章, 小阪 嘉之

  (公社)日本小児科学会, Mar. 2019, 日本小児科学会雑誌, 123(3) (3), 621 - 621, Japanese


• Atraumatic needle使用による腰椎穿刺後合併症の出現頻度

  菊池 菜摘, 岸本 健治, 市川 貴之, 中谷 尚子, 二野 菜々子, 中村 さやか, 田村 彰広, 山本 暢之, 神前 愛子, 斎藤 敦郎, 石田 敏章, 長谷川 大一郎, 小阪 嘉之

  (公社)日本小児科学会, Feb. 2019, 日本小児科学会雑誌, 123(2) (2), 266 - 266, Japanese


• 高リスク神経芽腫患者における化学療法中の筋肉量減少

  岸 奈津美, 岸本 健治, 中村 さやか, 市川 貴之, 中谷 尚子, 二野 菜々子, 田村 彰広, 山本 暢之, 神前 愛子, 斉藤 敦郎, 石田 敏章, 長谷川 大一郎, 小阪 嘉之

  (公社)日本小児科学会, Feb. 2019, 日本小児科学会雑誌, 123(2) (2), 317 - 317, Japanese


• Immunohistochemical Analysis for Predicting Prognosis in Hepatoblastoma

  Akihiro Tamura, Makiko Yoshida, Nobuyuki Yamamoto, Nanako Nino, Takayuki Ichikawa, Naoko Nakatani, Sayaka Nakamura, Atsuro Saito, Aiko Kozaki, Kenji Kishimoto, Toshiaki Ishida, Hiroaki Fukuzawa, Akiko Yokoi, Kosaku Maeda, Daiichiro Hasegawa, Eiso Hiyama, Yoshiyuki Kosaka

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S71 - S71, English

  Summary international conference


• Quantitation of Minimal Residual Disease by Droplet Digital PCR in High-Risk Neuroblastoma Patients

  Noriyuki Nishimura, Toshiaki Ishida, Khin Thwin, Suguru Uemura, Nobuyuki Yamamoto, Akihiro Tamura, Nanako Nino, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima

  WILEY, Nov. 2018, PEDIATRIC BLOOD & CANCER, 65, S38 - S39, English

  Summary international conference


• A pediatric ETV6-ABL1-positive acute lymphoblastic leukemia case with ETV6-ABL1-independent resistance to tyrosine kinase inhibitor

  Suguru Uemura, Daiichiro Hasegawa, Akemi Shono, Khin Kyae, Mon Thwin, Nanako Nino, Satoru Takafuji, Takeshi Mori, Akihiro Tamura, Nobuyuki Yamamoto, Atsuro Saito, Kenji Kishimoto, Toshiaki Ishida, Yoshiyuki Kosaka, Kazumoto Iijima, Noriyuki Nishimura

  AMER ASSOC CANCER RESEARCH, Oct. 2018, CANCER RESEARCH, 78(19) (19), English

  Summary international conference


• AYA世代ALLの寛解導入療法中に発症した脳静脈血栓症

  山本 暢之, 二野 菜々子, 田村 彰広, 中谷 尚子, 市川 貴之, 中村 さやか, 神前 愛子, 齋藤 敦郎, 岸本 健治, 石田 敏章, 米谷 昇, 石川 隆之, 石原 卓, 萩原 健一, 野上 恵嗣, 嶋 緑倫, 長谷川 大一郎, 小阪 嘉之

  (一社)日本小児血液・がん学会, Oct. 2018, 日本小児血液・がん学会雑誌, 55(4) (4), 312 - 312, Japanese


• 早期に遺伝子診断が得られ治療介入できた先天性葉酸吸収不全の一例

  市川 貴之, 石田 敏章, 中谷 尚子, 二野 菜々子, 中村 さやか, 田村 彰広, 山本 暢之, 神前 愛子, 斎藤 敦郎, 岸本 健治, 長谷川 大一郎, 河田 知子, 戸澤 雄介, 山田 雅文, 小坂 嘉之

  (一社)日本小児血液・がん学会, Oct. 2018, 日本小児血液・がん学会雑誌, 55(4) (4), 325 - 325, Japanese


• ELANE遺伝子変異を有する重症感染症を合併しない好中球減少症の1例(Long-term severe infection free survival with neutropenia due to ELANE mutation without G-CSF)

  中谷 尚子, 齋藤 敦郎, 市川 貴之, 二野 菜々子, 中村 さやか, 山本 暢之, 田村 彰広, 神前 愛子, 岸本 健治, 石田 敏章, 長谷川 大一郎, 唐川 修平, 川口 浩史, 小阪 嘉之

  (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1685 - 1685, English


• 兵庫県がん・生殖医療ネットワークにおける小児がん患者に対する卵巣組織凍結保存の試み

  中村 さやか, 岸本 健治, 藤原 隆弘, 太原 鉄平, 山本 暢之, 田村 彰広, 齋藤 敦郎, 神前 愛子, 石田 敏章, 長谷川 大一郎, 脇本 裕, 柴原 浩章, 小阪 嘉之

  (一社)日本小児血液・がん学会, Jun. 2018, 日本小児血液・がん学会雑誌, 55(1) (1), 61 - 61, Japanese


• 小児がん患者に対する粒子線治療の試み

  齋藤 敦郎, 中村 さやか, 藤原 隆弘, 太原 鉄平, 田村 彰広, 山本 暢之, 神前 愛子, 岸本 健治, 石田 敏章, 長谷川 大一郎, 河村 淳史, 鈴木 毅, 副島 俊典, 出水 祐介, 沖本 智昭, 長嶋 達也, 小阪 嘉之

  (公社)日本小児科学会, Apr. 2018, 日本小児科学会雑誌, 122(4) (4), 815 - 815, Japanese


• 小児がん患者における聴力障害発症頻度とリスク因子についての後方視的検討

  太原 鉄平, 石田 敏章, 中村 さやか, 藤原 隆弘, 田村 彰広, 山本 暢之, 神前 愛子, 齋藤 敦郎, 岸本 健治, 長谷川 大一郎, 勝沼 紗矢香, 大津 雅秀, 副島 俊典, 小阪 嘉之

  (公社)日本小児科学会, Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 230 - 230, Japanese


• 再発神経芽腫の臨床的検討

  石田 敏章, 太原 鉄平, 中村 さやか, 藤原 隆弘, 山本 暢之, 田村 彰広, 斎藤 敦郎, 神前 愛子, 岸本 健治, 吉田 牧子, 赤坂 好宣, 副島 俊典, 前田 貢作, 矢内 友子, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之

  (公社)日本小児科学会, Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 231 - 231, Japanese


• 本邦における小児がん治療時の深在性真菌症対策の現状 JCCG施設調査より

  福島 啓太郎, 篠田 邦大, 山本 暢之, 鈴木 孝二, 矢野 道広, 石田 裕二, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 豊田 秀実, 森 尚子

  (公社)日本小児科学会, Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 231 - 231, Japanese


• 小児急性白血病に対する化学療法の好中球減少期における予防的抗菌薬投与

  中村 さやか, 岸本 健治, 藤原 隆弘, 太原 鉄平, 田村 彰広, 山本 暢之, 神前 愛子, 齋藤 敦郎, 石田 敏章, 長谷川 大一郎, 小阪 嘉之

  (公社)日本小児科学会, Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 232 - 232, Japanese


• 5年以上のromiplostim投与後に無治療経過観察に至った幼児慢性免疫血小板減少性紫斑病

  森 健, 植村 優, 二野 菜々子, 榊原 菜々, 高藤 哲, 山本 暢之, 時政 定雄, 西村 範行, 飯島 一誠

  (公社)日本小児科学会, Feb. 2018, 日本小児科学会雑誌, 122(2) (2), 233 - 233, Japanese


• 【プライマリ・ケア医が知っておくべき小児悪性疾患】オンコロジック・エマージェンシー 乏尿・無尿

  山本 暢之, 長谷川 大一郎

  ＜Key Points＞(1)悪性腫瘍に伴う乏尿・無尿でも、腎前性・腎性・腎後性に分けて考える。(2)腎前性の乏尿では免疫能低下に伴う敗血症性ショックが重要である。(3)腎性では腫瘍崩壊症候群による急性腎不全への対応が重要である。(4)腎後性では腫瘍の浸潤による急性尿路閉塞、膀胱直腸障害を考える。(著者抄録)

  (株)東京医学社, Dec. 2017, 小児内科, 49(12) (12), 1761 - 1764, Japanese


• 本邦の小児がん化学療法における感染症対策の現状(第一報) 環境と検査 JCCG施設調査より

  篠田 邦大, 福島 啓太郎, 山本 暢之, 鈴木 孝二, 矢野 道広, 石田 裕二, 大曽根 眞也, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 嘉数 真理子, 加藤 陽子, 森 尚子, 水谷 修紀, 日本小児がん研究グループ(JCCG)

  (一社)日本小児血液・がん学会, Oct. 2017, 日本小児血液・がん学会雑誌, 54(4) (4), 370 - 370, Japanese


• 本邦における小児がん化学療法に対する感染症対策の現状(第二報) 予防と治療 JCCG施設調査より

  篠田 邦大, 福島 啓太郎, 山本 暢之, 鈴木 孝二, 矢野 道広, 石田 裕二, 大曽根 眞也, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 嘉数 真理子, 加藤 陽子, 森 尚子, 水谷 修紀, 日本小児がん研究グループ(JCCG)

  (一社)日本小児血液・がん学会, Oct. 2017, 日本小児血液・がん学会雑誌, 54(4) (4), 370 - 370, Japanese


• 本邦における小児がん患者の食事管理に関する現状調査 JCCG施設調査より

  鈴木 孝二, 福島 啓太郎, 山本 暢之, 篠田 邦大, 矢野 道広, 石田 裕二, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 斎藤 雄弥, 佐野 弘純, 澤田 明久, 新小田 雄一, 森 尚子, 水谷 修紀, 日本小児がん研究グループ(JCCG)

  (一社)日本小児血液・がん学会, Oct. 2017, 日本小児血液・がん学会雑誌, 54(4) (4), 370 - 370, Japanese


• 本邦における小児がん患者に対する口腔ケアの現状 JCCG施設調査より

  山本 暢之, 福島 啓太郎, 鈴木 孝二, 篠田 邦大, 斎藤 雄弥, 澤田 明久, 石田 裕二, 嘉数 真理子, 森 尚子, 加藤 陽子, 新小田 雄一, 大曽根 眞也, 佐野 弘純, 矢野 道広, 水谷 修紀

  (一社)日本小児血液・がん学会, Oct. 2017, 日本小児血液・がん学会雑誌, 54(4) (4), 371 - 371, Japanese


• 胸部CTにより速やかに診断し得たX連鎖性重症複合型免疫不全症の乳児

  鮫島 智大, 藤村 順也, 中西 啓太, 高藤 哲, 坊 亮輔, 山本 暢之, 森 健, 早川 晶, 西村 範行, 藤井 栄一, 宅見 徹, 飯島 一誠

  (公社)日本小児科学会, May 2017, 日本小児科学会雑誌, 121(5) (5), 914 - 914, Japanese


• PET-MRI所見に基づく肺・下鼻甲介・腎生検が原疾患の診断に有効であった二次性血球貪食性リンパ組織球症の1例

  河原 仁守, 尾藤 祐子, 會田 洋輔, 橘木 由美子, 中井 優美子, 清水 奈保子, 眞庭 謙昌, 西井 達矢, 伊藤 智雄, 藤村 順也, 忍頂寺 毅史, 高藤 哲, 坊 亮輔, 山本 暢之, 森 健, 西村 範行, 飯島 一誠

  (一社)日本小児血液・がん学会, Nov. 2016, 日本小児血液・がん学会雑誌, 53(4) (4), 349 - 349, Japanese


• G-CSF投与と自家末梢血幹細胞移植を併用しbi-weekly VDC-IE療法を完遂し得た切除不能ユーイング肉腫例

  山本 暢之, 坊 亮輔, 高藤 哲, 森 健, 西村 範行, 江島 泰生, 深瀬 直政, 原 仁美, 河本 旭哉, 秋末 敏宏, 飯島 一誠

  (一社)日本小児血液・がん学会, Nov. 2016, 日本小児血液・がん学会雑誌, 53(4) (4), 298 - 298, Japanese


• Spectral shaping+高ピッチ二重らせん撮影による低線量胸部CT

  西井 達矢, 田中 宇多留, 香川 清澄, 杉岡 勇典, 山本 暢之, 森 健, 早川 晶, 高橋 哲, 杉村 和朗

  日本小児放射線学会, Jun. 2016, 日本小児放射線学会雑誌, 32(Suppl.) (Suppl.), 23 - 23, Japanese


• メチルプレドニゾロンの吸収不良により造血細胞移植後急性移植片対宿主病のコントロールに難渋した小児急性リンパ性白血病の1症例

  田中 雄大, 山本 和宏, 大澤 史宜, 早川 晶, 山本 暢之, 森 健, 岡本 千明, 山下 和彦, 西岡 達也, 久米 学, 槇本 博雄, 平井 みどり

  (一社)日本TDM学会, May 2016, TDM研究, 33(2) (2), 172 - 172, Japanese


• 化学療法後の好中球減少期に血栓性静脈炎によりメチシリン耐性表皮ブドウ球菌の持続菌血症を呈した急性骨髄性白血病の1例

  森 健, 山村 智彦, 南川 将吾, 西井 達矢, 杉岡 勇典, 工藤 史明, 大路 剛, 久松 千恵子, 平瀬 敏志, 山本 暢之, 久保川 育子, 早川 晶

  (一社)日本小児血液・がん学会, Apr. 2016, 日本小児血液・がん学会雑誌, 53(1) (1), 31 - 31, Japanese


• 化学療法後の好中球減少期に血栓性静脈炎によりメチシリン耐性表皮ブドウ球菌の持続菌血症を呈した急性骨髄性白血病の1例

  森健, 山村智彦, 南川将吾, 西井達矢, 杉岡勇典, 工藤史明, 大路剛, 久松千恵子, 平瀬敏志, 山本暢之, 久保川育子, 早川晶

  2016, 日本小児血液・がん学会雑誌(Web), 53(1) (1)


• G-CSF投与と自家末梢血幹細胞移植を併用しbi-weekly VDC-IE療法を完遂し得た切除不能ユーイング肉腫例

  山本暢之, 坊亮輔, 高藤哲, 森健, 西村範行, 江島泰生, 深瀬直政, 原仁美, 河本旭哉, 秋末敏宏, 飯島一誠

  2016, 日本小児血液・がん学会雑誌(Web), 53(4) (4)


• 左鎖骨部腫瘤を呈した生後6ヵ月の乳児例

  森 健, 藤村 順也, 堀之内 智子, 南川 将吾, 平瀬 敏志, 山本 暢之, 久保川 育子, 早川 晶, 西村 範行, 榊原 俊介, 寺師 浩人, 飯島 一誠

  (公社)日本小児科学会, Jan. 2016, 日本小児科学会雑誌, 120(1) (1), 84 - 84, Japanese


• 外来化学療法中(ALL B12臨床試験)の中心静脈カテーテルの管理についての検討

  山本 暢之, 堀之内 智子, 藤村 順也, 森 健, 早川 晶, 西村 範行, 飯島 一誠

  (一社)日本小児血液・がん学会, Oct. 2015, 日本小児血液・がん学会雑誌, 52(4) (4), 342 - 342, Japanese


• 神経芽腫の発症・進展におけるRab6BとRab28の役割

  西村 範行, 山本 暢之, 長谷川 大一郎

  日本癌学会, Oct. 2015, 日本癌学会総会記事, 74回, J - 1346, English


• DENNドメイン蛋白質DENND2Aによる神経芽腫発の発症・進展の制御機構

  山本 暢之, 西村 範行, 長谷川 大一郎

  日本癌学会, Oct. 2015, 日本癌学会総会記事, 74回, P - 3035, English


• 骨髄移植後のKaufmann療法中に肝腫瘤を認めた1例

  森 健, 加藤 威, 平瀬 敏志, 山本 暢之, 久保川 育子, 矢内 友子, 早川 晶, 竹島 泰弘, 西井 達矢, 瀬尾 靖

  (一社)日本小児血液・がん学会, Aug. 2015, 日本小児血液・がん学会雑誌, 52(2) (2), 176 - 176, Japanese


• 神戸こども初期急病センターにおける同日複数回受診患児についての検討

  石橋 和人, 石田 明人, 井上 祐司, 片山 以登, 児玉 真美, 植松 女久美, 安井 美佳, 尾崎 美恵, 森岡 一朗, 森貞 直哉, 池田 真理子, 山本 暢之, 松野下 夏樹, 忍頂寺 毅史

  (一社)日本小児救急医学会, Jun. 2015, 日本小児救急医学会雑誌, 14(2) (2), 305 - 305, Japanese


• 化学療法中に血液培養陽性となった急性リンパ球白血病症例の臨床的検討

  山本 暢之, 山村 智彦, 南川 将吾, 平瀬 敏志, 久保川 育子, 森 健, 早川 晶, 西村 範行, 飯島 一誠

  (公社)日本小児科学会, Feb. 2015, 日本小児科学会雑誌, 119(2) (2), 410 - 410, Japanese


• 骨髄移植後のKaufmann療法中に肝腫瘤を認めた1例

  森健, 加藤威, 平瀬敏志, 山本暢之, 久保川育子, 矢内友子, 早川晶, 竹島泰弘, 西井達矢, 瀬尾靖

  2015, 日本小児血液・がん学会雑誌(Web), 52(2) (2)


• Induction of ALDH1A2 expression is critical for cancer stem cell properties in neuroblastoma

  Noriyuki Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham, Nobuyuki Yamamoto, Satoshi Hrase, Akira Hayakawa, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Yasuhiro Takeshima, Kazumoto Iijima, Hisahide Nishio

  AMER ASSOC CANCER RESEARCH, Oct. 2014, CANCER RESEARCH, 74(19) (19), English

  Summary international conference


• 神経芽腫がん幹細胞の発生・分化における細胞内小胞輸送の制御因子Rab6Bの役割(Role of a membrane traffic regulator Rab6B in the development of cancer stem cells in neuroblastoma)

  西村 範行, ファム・ティファン・ヒュエン, ハルトモトリブディ, 山本 暢之, 平瀬 敏志, 早川 晶, 矢内 友子, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, 松尾 雅文, 飯島 一誠, 西尾 久英

  (一社)日本小児血液・がん学会, Oct. 2014, 日本小児血液・がん学会雑誌, 51(4) (4), 250 - 250, English

  Meeting report


• 化学療法中に虫垂炎を発症した小児悪性腫瘍症例の検討(Acute appendicitis of cancer children during chemotherapy: A single center experience)

  山本 暢之, 山村 智彦, 平瀬 敏志, 久保川 育子, 森 健, 早川 晶, 西村 範行, 會田 洋輔, 久松 千恵子, 前田 貢作, 飯島 一誠

  (一社)日本小児血液・がん学会, Oct. 2014, 日本小児血液・がん学会雑誌, 51(4) (4), 233 - 233, English

  Meeting report


• 顔貌と胆汁うっ滞をきっかけとして診断に至ったAlagille症候群の1例

  加藤 威, 神吉 直宙, 平瀬 敏志, Yamamoto Nobuyuki, 久保川 育子, 森 健, Ikeda Mariko, 矢内 友子, 早川 晶, 飯島 一誠

  (公社)日本小児科学会, Jun. 2014, 日本小児科学会雑誌, 118(6) (6), 959 - 959, Japanese

  Meeting report


• 骨髄移植後の卵巣機能障害に対するKaufmann療法中に肝線維腫を発症したALLの一例

  森健, 早川晶, 西田浩輔, 平瀬敏志, 山本暢之, 久保川育子, 西井達矢, 山崎隆, 伊藤智雄, 瀬尾靖, 竹島泰宏, 山崎峰夫, 飯島一誠

  2014, 日本造血細胞移植学会総会プログラム・抄録集, 36th


• Romiplostim Therapy in a Child with Refractory Chronic Immune Thrombocytopenia

  HIRASE Satoshi, NISHIDA Kosuke, MATSUNOSHITA Natsuki, YAMAMOTO Nobuyuki, NINCHOJI Takeshi, MORI Takeshi, OYAZATO Yoshinobu, YANAI Tomoko, HAYAKAWA Akira, TAKESHIMA Yasuhiro, IIJIMA Kazumoto

  1歳男児。紫斑を主訴とした。前医で免疫性血小板減少性紫斑と診断され、γグロブリン静注やプレドニゾロン経口投与が行われたが、効果は一過性であった。リツキシマブなどの種々の薬剤を投与したが全て無効であった。唯一デキサメサゾンパルス療法に効果を認めたが、一時的であった。しかし、頭部打撲による皮下血腫や鼻出血を頻回に認めたため、同治療を繰り返した。脾摘も考慮したが、手術に必要な血小板数を得ることが出来ず断念した。発症後6ヵ月からロミプロスチム(A)1μg/kg/週の投与を開始したところ、Aの増量、γグロブリン療法、血小板輸血による管理で血小板数が増加した。Aの投与開始から3ヵ月後に最大量である10μg/kg/週まで増量したが、血小板数1万/μlを維持できる様になり、出血傾向もなくなった。その後はAの10μg/kg/週の単独投与で外来治療を行った。Aの投与開始から1年後の現在、Aに関連する有害事象は認めていない。

  日本小児科学会, Oct. 2013, 日本小児科学会雑誌, 117(10) (10), 1640 - 1644, Japanese


• 乳児血管腫に対するプロプラノロール内服療法の有用性について

  山下和彦, 赤澤由子, 山口由加里, 平瀬敏志, 加藤威, 山本暢之, 久保川育子, 森健, 矢内友子, 久米学, 槇本博雄, 平野剛, 早川晶, 平井みどり

  日本医療薬学会, 28 Aug. 2013, 日本医療薬学会年会講演要旨集, 23rd, 218 - 218, Japanese


• 積極的治療にて救命し長期間寛解を維持している頭蓋内出血合併急性前骨髄球性白血病の1例

  矢内友子, 加藤威, 平瀬敏志, 山本暢之, 久保川育子, 森健, 早川晶, 竹島泰弘, 飯島一誠

  (一社)日本小児救急医学会, May 2013, 日本小児救急医学会雑誌, 12(2) (2), 195 - 195, Japanese


• 哺乳不良・体重増加不良にて発症し著明な高カルシウム血症を呈した悪性腎腫瘍の1乳児例

  久保川育子, 加藤威, 平瀬敏志, 山本暢之, 石森真吾, 忍頂寺毅史, 中川卓, 森貞直哉, 池田真理子, 森健, 矢内友子, 早川晶, 竹島泰弘, 飯島一誠

  (一社)日本小児救急医学会, May 2013, 日本小児救急医学会雑誌, 12(2) (2), 276 - 276, Japanese


• 抗Jka自己抗体を検出したIgA欠損症を伴うEvans症候群の一例

  Hayakawa Akira

  (一社)日本輸血・細胞治療学会, Apr. 2013, 日本輸血細胞治療学会誌, 59(2) (2), 330 - 330, Japanese

  Meeting report


• ビタミンB12欠乏性貧血を発症したDown症候群の乳児例

  Hayakawa Akira

  (公社)日本小児科学会, Feb. 2013, 日本小児科学会雑誌, 117(2) (2), 369 - 369, Japanese

  Meeting report


• 乳児血管腫に対するβ遮断薬の治療経験

  矢内友子, 神吉直宙, 加藤威, 松野下夏樹, 平瀬敏志, 山本暢之, 江尻浩隆, 久保川育子, 三輪明弘, 森健, 森岡一朗, 早川晶, 竹島泰弘, 飯島一誠

  (公社)日本小児科学会, Jan. 2013, 日本小児科学会雑誌, 117(1) (1), 145 - 145, Japanese


• 電撃性紫斑病にて発症した先天性Protein C欠損症の新生児例

  Hayakawa Akira

  (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2012, 日本小児血液・がん学会学術集会、日本小児がん看護学会、公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号54回・10回・17回, 54回・10回・17回, 374 - 374, Japanese

  Meeting report


• 初診時に高Ca血症を認めた小児悪性腫瘍3例の臨床的検討

  Hayakawa Akira

  (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2012, 日本小児血液・がん学会学術集会，日本小児がん看護学会，公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号54回・10回・17回, 54回・10回・17回, 334 - 334, Japanese

  Meeting report


• 神経芽腫症例におけるmultiple real‐time RT‐PCR markerを用いた微小残存病変(MRD)解析

  田中愛子, 長谷川大一郎, HARTOMO Tri Budi, 山本暢之, 宮田憲二, 越智聡史, 斎藤敦郎, 山下達也, 石田敏章, 川崎圭一郎, 松尾雅文, PHAM Thi Van Huyen, 大橋浩基, 森健, 矢内友子, 早川晶, 竹島泰弘, 小阪嘉之, 飯島一誠, 西尾久英, 西村範行

  (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会, Nov. 2012, 日本小児血液・がん学会学術集会・日本小児がん看護学会・がんの子供を守る会公開シンポジウムプログラム・総会号, 54回・10回・17回, 291 - 291, Japanese


• 免疫性血小板減少症治療中の重症肺炎・ARDSに対しECMOを2回長期導入し救命し得た幼児例

  平瀬敏志, 矢内友子, 久松千恵子, 加納寛也, 谷岡怜, 北博志, 神吉直宙, 加藤威, 松野下夏樹, 山本暢之, 久保川育子, 粟野宏之, 森健, 早川晶, 竹島泰弘, 飯島一誠

  日本小児呼吸器学会, Aug. 2012, 日本小児呼吸器疾患学会雑誌, 23(Suppl.) (Suppl.), 120 - 120, Japanese


• ヒトパルボウイルスB19感染症により血液学的異常を呈した6例の臨床的検討

  早川晶, 平瀬敏志, 松野下夏樹, 山本暢之, 忍頂寺毅史, 久保川育子, 森健, 矢内友子, 竹島泰弘, 飯島一誠

  (公社)日本小児科学会, Feb. 2012, 日本小児科学会雑誌, 116(2) (2), 273 - 273, Japanese


• 非血縁者間同種骨髄移植後にEBV関連リンパ増殖症および血球貪食症候群を合併し致死的経過をとった未分化大細胞性リンパ腫の1例

  山本暢之, 平瀬敏志, 松野下夏樹, 森健, 矢内友子, 早川晶, 竹島泰弘, 飯島一誠, 松尾雅文

  01 Feb. 2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 298, Japanese


• バルガンシクロビル内服治療により聴性脳幹反応異常が改善した先天性サイトメガロウィルス感染症の2例

  松尾 希世美, 森岡 一朗, 香田 翼, 山本 暢之, 横田 知之, 藤岡 一路, 森川 悟, 三輪 明弘, 柴田 暁男, 早川 晶, 横山 直樹, 松尾 雅文

  (公社)日本小児科学会, Dec. 2011, 日本小児科学会雑誌, 115(12) (12), 1937 - 1937, Japanese


• 初診時急性白血病様所見を呈した胞巣型横紋筋肉腫の1例

  山本暢之, 平瀬敏志, 松野下夏樹, 森健, 矢内友子, 早川晶, 西村範行, 竹島泰弘, 飯島一誠, 松尾雅文

  (NPO)日本小児がん学会, Nov. 2011, 日本小児血液・がん学会学術集会・日本小児がん看護学会・がんの子供を守る会公開シンポジウムプログラム・総会号, 48(プログラム・総会号) (プログラム・総会号), 341 - 341, Japanese


• 小児同種造血幹細胞移植におけるGFRの指標としての血清シスタチンCの有用性の検討

  矢内 友子, 平瀬 敏志, 松野下 夏樹, 山本 暢之, 忍頂寺 毅史, 久保川 育子, 森 健, 早川 晶, 松尾 雅文

  (一社)日本血液学会-東京事務局, Sep. 2011, 臨床血液, 52(9) (9), 1242 - 1242, Japanese


• 初診時、播種性血管内凝固症候群(DIC)を発症、急性白血病が疑われた胞巣型横紋筋肉腫の一症例

  岡崎 葉子, 菊間 知恵, 東口 佳苗, 山下 智江, 小林 曜子, 木下 承晧, 山本 暢之, 森 健, 早川 晶, 河野 誠司

  (一社)日本検査血液学会, Jun. 2011, 日本検査血液学会雑誌, 12(学術集会) (学術集会), S93 - S93, Japanese


• 全身性けいれんと意識障害で発症した中枢神経系ループスの6歳例

  西山 将広, 濱平 陽史, 植村 加奈子, 二階堂 量子, 山本 寛子, 岸田 真, 北山 路子, 山本 暢之, 上田 陽子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 五百蔵 智明, 久呉 真章

  6歳男児。持続する発熱、前腕・頬部の紅斑、肝機能異常を主訴とした。入院時、リンパ球減少を認めた。入院6時間後、全身性強直間代痙攣が出現し、気管挿管下に高容量チオペンタールを投与し、2時間後にようやく痙攣が頓挫した。チオペンタール中止後も意識障害は4日間遷延した。頭部CTで明らかな異常を認めなかったが、脳症または中枢神経系ループスを疑い、入院1日目からマンニトールとアシクロビルの静脈投与を開始し、3日目からステロイドパルス療法を開始したところ意識障害は改善した。同日抗核抗体2560倍、抗ds-DNA抗体105.6IU/mLを認め、小児全身性エリトマトーデスの診断基準12項目中6項目を満たしており、診断が確定した。入院12日目から13日目にメチルプレドニゾロン・パルス療法、13日目からプレドニゾロンとミゾリビンを開始した。入院19日目に施行した腎生検より、ループス腎炎のI型に分類した。以降、神経学的後遺症を認めず、入院43日目に退院した。発症から1年半が経過し、プレドニゾロン6mg/日まで減量したが、症状の再燃はなかった。

  (公社)日本小児科学会, Mar. 2011, 日本小児科学会雑誌, 115(3) (3), 611 - 615, Japanese


• 当院におけるユーイング肉腫ファミリー腫瘍の治療成績

  山本 暢之, 忍頂寺 毅史, 久保川 育子, 森 健, 矢内 友子, 早川 晶, 松尾 雅文

  (公社)日本小児科学会, Feb. 2011, 日本小児科学会雑誌, 115(2) (2), 493 - 493, Japanese


• 一児が臍帯ヘルニアであった一絨毛膜二羊膜性双胎の2例

  植村 加奈子, 二階堂 量子, 山本 寛子, 岸田 真, 山本 暢之, 西山 将広, 北山 路子, 上田 陽子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Dec. 2010, 日本小児科学会雑誌, 114(12) (12), 1939 - 1939, Japanese


• 精神症状を主訴とした14歳女児のBasedow病の1例

  二階堂 量子, 山本 寛子, 植村 加奈子, 山本 暢之, 西山 将広, 北山 路子, 岸田 真, 上田 陽子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章, 丸山 準

  (公社)日本小児科学会, Dec. 2010, 日本小児科学会雑誌, 114(12) (12), 1941 - 1941, Japanese


• 生来健康な児に発症したサイトメガロウイルス肝炎の1例

  山本 寛子, 植村 加奈子, 二階堂 量子, 岸田 真, 北山 路子, 西山 将広, 山本 暢之, 上田 陽子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Dec. 2010, 日本小児科学会雑誌, 114(12) (12), 1942 - 1942, Japanese


• タンデム自家末梢血幹細胞移植後2年間寛解維持している初診時骨髄転移陽性Ewing肉腫の1例

  久保川育子, 山本暢之, 忍頂寺毅史, 森健, 矢内友子, 早川晶, 岸本健太, 秋末敏宏, 竹島泰弘, 松尾雅文

  (NPO)日本小児がん学会, Dec. 2010, 日本小児血液学会・日本小児がん学会・日本小児がん看護学会・財団法人がんの子供を守る会公開シンポジウムプログラム・総会号, 47(プログラム・総会号) (プログラム・総会号), 302 - 302, Japanese


• 経口鉄キレート療法後のRISTにて速やかな生着と造血の回復を認めたDiamond‐Blackfan Anemiaの16歳女児例

  早川晶, 石森真吾, 山本暢之, 忍頂寺毅史, 久保川育子, 森健, 矢内友子, 上村裕保, 住永亮, 竹島泰弘, 松尾雅文

  (一社)日本血液学会-東京事務局, Sep. 2010, 臨床血液, 51(9) (9), 1279 - 1279, Japanese


• 全身性痙攣で発症しステロイドパルス療法が奏功したCNSループスの1例

  西山 将広, 濱平 陽史, 植村 加奈子, 二階堂 量子, 山本 寛子, 岸田 真, 北山 路子, 山本 暢之, 上田 陽子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 五百蔵 智明, 久呉 真章

  6歳男児。患者は持続する発熱、紅斑、肝機能障害を主訴とした。当初、意識は清明で、額、頬、上肢等の紅斑、リンパ球減少が認められた。しかし、入院6時間後に突然の全身痙攣と意識障害が出現し、ミダゾラム、フェニトインの静脈内投与が施行されるも、痙攣は持続し、高容量チオペンタールを気管挿管下に投与されたが、頓挫した。一方、チオペンタールは入院2日目に終了したが、JCS 3桁の意識障害は4日間遷延した。更に入院3日目からCNSループスまたは脳症が疑われ、3日間メチルプレドニゾロン・パルス療法を施行したところ、次第に意識レベルが改善した。以上、これらの臨床経過に加え、抗核抗体2560倍、抗ds-DNA抗体105.6IU/mL等から、本症例は全身性エリトマトーデスと診断され、メチルプレドニゾロン・パルス療法の2クール目を施行し、あわせてプレドニゾロン、ミゾリビンを開始した結果、経過は良好で、患者は神経学的後遺症を残さず退院となった。尚、6歳以下で初診時に痙攣と意識障害を来したCNSループスの報告は、検索した限り認められなかった。

  姫路赤十字病院図書学術委員会, Jul. 2010, 姫路赤十字病院誌, 34, 13 - 18, Japanese


• Basedow病の診断時に僧帽弁逸脱を認めた2歳女児の1例

  岸田 真, 山本 暢之, 西山 将広, 北山 路子, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Dec. 2009, 日本小児科学会雑誌, 113(12) (12), 1894 - 1894, Japanese


• 当院における胃食道逆流症例の検討

  山本 暢之, 植村 加奈子, 二階堂 量子, 山本 寛子, 北山 路子, 岸田 真, 西山 将広, 李 知子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章, 畠山 理, 大片 祐一

  (公社)日本小児科学会, Dec. 2009, 日本小児科学会雑誌, 113(12) (12), 1896 - 1896, Japanese


• 小児疾患の身近な漢方治療 インフルエンザ・感冒性嘔吐下痢症を中心に

  岸本 芽子, 北山 路子, 岸田 真, 山本 暢之, 西山 将広, 李 知子, 伴 紘文, 住谷 珠子, 高見 勇一, 柄川 剛, 高橋 宏暢, 濱平 陽史, 五百蔵 智明, 久呉 真章

  姫路赤十字病院図書学術委員会, Jun. 2009, 姫路赤十字病院誌, 33, 136 - 136, Japanese


• 当院における髄膜炎起炎菌と抗生剤感受性に関する検討

  山本 暢之, 岸田 真, 北山 路子, 西山 将広, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  過去5年間に細菌性髄膜炎と診断され、治療を行った児38症例の、その入院時における髄液培養の結果を基に、起炎菌と抗生剤の感受性について後方視的に検討した。1)起炎菌が判明したのは28例で、インフルエンザ菌20例、肺炎球菌4例、大腸菌3例、B群溶血性連鎖球菌1例であった。2)インフルエンザ菌・大腸菌に対してはCTX・CTRX・MEPMが良好な感受性を示した。3)PAPM/BPについては試験をしたほぼすべての株において耐性を示した。肺炎球菌についてもPAPM/BPは耐性であるものが多く、CTX・MEPMが比較的良好な感受性を示した。VCMは全例で感受性を示した。3)これらの結果を踏まえ、初期に使用する抗生剤はPAPM/BPからMEPMに変更された。但し、今後も時期をおいて感受性を検討する必要があると考えられた。

  姫路赤十字病院図書学術委員会, Jun. 2009, 姫路赤十字病院誌, 33, 11 - 14, Japanese


• 低血糖と意識障害をきっかけに診断されたプロピオン酸血症の1例

  西山 将広, 鄭 聡柄, 岸田 真, 北山 路子, 山本 暢之, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 604 - 604, Japanese


• 新生児におけるくも膜下出血と初期嘔吐の臨床像の比較

  岸田 真, 山本 暢之, 西山 将広, 北山 路子, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 604 - 604, Japanese


• 発熱を主訴に当院に入院した新生児74例の検討

  北山 路子, 岸田 真, 西山 将広, 山本 暢之, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 605 - 605, Japanese


• 当科における腹腔鏡下鼠径ヘルニア手術(LPEC法)の導入

  畠山 理, 大片 祐一, 岸田 真, 北山 路子, 西山 将広, 山本 暢之, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 605 - 606, Japanese


• 当院における髄膜炎起炎菌と抗生剤感受性に関する検討

  山本 暢之, 岸田 真, 北山 路子, 西山 将広, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 608 - 608, Japanese


• 抗SS-B抗体陽性であったエルシニア感染症の1例

  西山 将広, 岸田 真, 北山 路子, 山本 暢之, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 柄川 剛, 高橋 宏暢, 岸本 芽子, 濱平 陽史, 五百蔵 智明, 久呉 真章

  (公社)日本小児科学会, Mar. 2009, 日本小児科学会雑誌, 113(3) (3), 608 - 608, Japanese


• 当院での川崎病におけるIVIG療法不応症例の検討

  山本 暢之, 岸田 真, 北山 路子, 西山 将広, 李 知子, 住谷 珠子, 伴 紘文, 高見 勇一, 鄭 聡柄, 柄川 剛, 高橋 宏暢, 濱平 陽史, 五百蔵 智明, 久呉 真章

  日本赤十字社医学会, Sep. 2008, 日赤医学, 60(1) (1), 241 - 241, Japanese


• シクロフォスファミドが有効であった小児難治性ネフローゼ症候群の2例

  浜平 陽史, 岸田 真, 北山 路子, 西山 将広, 山本 暢之, 伴 紘文, 住谷 珠子, 高見 勇一, 柄川 剛, 鄭 聡柄, 高橋 宏暢, 五百蔵 智明, 久呉 真章, 吉川 徳茂

  日本赤十字社医学会, Sep. 2008, 日赤医学, 60(1) (1), 242 - 242, Japanese

• PET-MRI所見に基づく肺・下鼻甲介・腎生検が原疾患の診断に有効であった二次性血球貪食リンパ組織球症の1例

  河原仁守, Bito Yuko, 会田洋輔, 橘木由美子, 中井優美子, Shimizu Nahoko, 真庭謙昌, Nishii Tatsuya, Itoh Tomoo, 藤村順也, Ninchoji Takeshi, 高藤 哲, 坊 亮輔, Yamamoto Nobuyuki, Mori Takeshi, Nishimura Noriyuki, Iijima Kazumoto

  第58回日本小児血液・がん学会学術集会, Dec. 2016, Japanese, 日本小児血液・がん学会, 東京, Domestic conference

  Poster presentation


• G-CSF投与と自家末梢血幹細胞移植を併用しbi-weekly VDC-IE療法を完遂し得た切除不能ユーイング肉腫例

  Yamamoto Nobuyuki, 坊 亮輔, 高藤 哲, Mori Takeshi, Nishimura Noriyuki, Ejima Yasuo, Hara Hitomi, Kawamoto Teruya, Akisue Toshihiro, Iijima Kazumoto

  第58回日本小児血液・がん学会学術集会, Dec. 2016, Japanese, 日本小児血液・がん学会, 東京, Domestic conference

  Oral presentation


• Reemergence of a translocation t(11;19)(q23;p13.1) in the absence of leukemia

  Saito A, Hasegawa D, Uemura S, Nino N, Takafuji S, Yokoi T, Tahara T, Tamura A, Kozaki A, Kishimoto K, Ishida Tatsuro, Kawasaki K, Yamamoto Nobuyuki, Mori Takeshi, Nishimura Noriyuki, Kosaka Y

  第79回日本血液学会学術集会, Oct. 2016, Japanese, 日本血液学会, 横浜, Domestic conference

  Poster presentation


• Aggressive double-hit leukemia/lymphoma with t(14;18)(q32;q21) and t(8;21)(q24;q11.2)

  Uemura S, Hasegawa D, Nino N, Takafuji S, Yokoi T, Tahara T, Tamura A, Saito A, Kozaki A, Kishimoto K, Ishida Tatsuro, Kawasaki K, Yamamoto Nobuyuki, Mori Takeshi, Hayakawa A, Nishimura Noriyuki, Kosaka Y

  第78回日本血液学会学術集会, Oct. 2016, Japanese, 日本血液学会, 横浜, Domestic conference

  Poster presentation


• Spectral shaping+高ピッチ二重らせん撮影による低線量胸部CT

  Nishii Tatsuya, 田中宇多留, 香川清澄, 杉岡勇典, Yamamoto Nobuyuki, Mori Takeshi, 早川晶, Takahashi Satoru, 杉村和朗

  第52回小児放射線学会学術集会, Jun. 2016, Japanese, 日本小児放射線学会, 東京, Domestic conference

  Oral presentation


• Rab6B mediates the progression of neuroblastoma through the interaction with MTMR5

  Nishimura Noriyuki, Pham TVH, Thwin KK, Yamamoto Nobuyuki, Mori Takeshi, Hayakawa A, Nishio Hisahide, Matsuo M, Hasegawa D, Kawasaki K, Kosaka Y, Iijima Kazumoto

  Advances in Neuroblastoma Research Conference 2016, Jun. 2016, English, Advances in Neuroblastoma Research Conference, Cairns, Australia, International conference

  Poster presentation


• DENN domain protein DENND2A regulates the progression of neuroblastoma.

  Yamamoto Nobuyuki, Thwin KK, Fujimura J, Nakanishi K, Mori Takeshi, Hayakawa A, Nishio Hisahide, Matsuo M, Hasegawa D, Kawasaki K, Kosaka Y, Iijima Kazumoto, Nishimura Noriyuki

  Advances in Neuroblastoma Research Conference 2016, Jun. 2016, English, Advances in Neuroblastoma Research Conference, Cairns, Australia, International conference

  Poster presentation


• Minimal residual disease monitoring in neuroblastoma patients.

  Nishimura Noriyuki, トゥインキン キモン, Yamamoto Nobuyuki, Mori Takeshi, 早川 晶, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, Nishio Hisahide, Iijima Kazumoto

  The 119th Annual Meeting of the Japan Pedeatric Society, May 2016, Japanese, Japan Pediatric Society, 札幌, Domestic conference

  Oral presentation


• メチルプレドニゾロンの吸収不良により造血細胞移植後急性移植片対宿主病のコントロールに難渋した小児急性リンパ性白血病の1症例

  田中雄大, 山本和宏, 大澤史宜, 早川晶, Yamamoto Nobuyuki, Mori Takeshi, 岡本千明, 山下和彦, 西岡達也, 久米学, 槇本博雄, Hirai Midori

  第33回日本TDM学会学術大会, May 2016, Japanese, 日本TDM学会, 栃木, Domestic conference

  Poster presentation


• メチルプレドニゾロンの吸収不良により造血細胞移植後急性移植片対宿主病のコントロールに難渋した急性リンパ性白血病の1症例

  田中 雄大, 山本 和宏, 大澤 史宜, 早川 晶, Yamamoto Nobuyuki, Mori Takeshi, 岡本 千明, 山下 和彦, 西岡 達也, 久米 学, 槇本 博雄, Hirai Midori

  第33回日本TDM学会・学術大会, May 2016, Japanese, 日本TDM学会, 宇都宮, Domestic conference

  Poster presentation


• Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

  植村 優, Yamamoto Nobuyuki, 神前 愛子, 二野 菜々子, 高藤 哲, 横井 健人, 齋藤 敦郎, 石田 敏章, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, 平瀬 聡史, Mori Takeshi, Hayakawa Akira, Iijima Kazumoto, Nishio Hisahide, Nishimura Noriyuki

  The 57th Annual Meeting of the Japanese Society of Pediatric Hematology / Oncology, Nov. 2015, Japanese, The Japanese Society of Pediatric Hematology / Oncology, 甲府市, Domestic conference

  Oral presentation


• 外来化学療法中（ALL B12臨床試験）の中心静脈カテーテルの管理についての検討

  Yamamoto Nobuyuki, 堀之内智子, 藤村順也, Mori Takeshi, Hayakawa Akira, Nishimura Noriyuki, Iijima Kazumoto

  第57回日本小児血液がん学会学術集会, Nov. 2015, Japanese, 日本小児血液がん学会, 山梨, Domestic conference

  Poster presentation


• Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

  Suguru Uemura, Yamamoto Nobuyuki, Aiko Kozaki, Nanako Nino, Satoshi Takafuji, Takehito Yokoi, Atsuro Saito, Toshiaki Ishida, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Mori Takeshi, Hayakawa Akira, Iijima Kazumoto, Nishio Hisahide, Nishimura Noriyuki

  第57回日本小児血液がん学会学術集会, Nov. 2015, Japanese, 日本小児血液がん学会, 山梨, Domestic conference

  Oral presentation


• DENN domain protein DENND2A mediates the progression of neuroblastoma

  Yamamoto Nobuyuki, 堀之内 智子, 藤村 順也, Mori Takeshi, Hayakawa Akira, 長谷川 大一郎, 小阪 嘉之, Nishio Hisahide, Iijima Kazumoto, Nishimura Noriyuki

  The 57th Annual Meeting of the Japanese Society of Pediatric Hematology / Oncology, Nov. 2015, Japanese, The Japanese Society of Pediatric Hematology / Oncology, 甲府市, Domestic conference

  Oral presentation


• DENN domain protein DENND2A mediates the progression of neuroblastoma.

  Yamamoto Nobuyuki, Horinouchi Tomoko, Fujimura Junya, Mori Takeshi, Hayakawa Akira, Hasegawa Daiichiro, Kosaka Yoshiyuki, Nishio Hisahide, Iijima Kazumoto, Nishimura Noriyuki

  第57回日本小児血液がん学会学術集会, Nov. 2015, Japanese, 日本小児血液がん学会, 山梨, Domestic conference

  Oral presentation


• 神経芽腫の発症・進展におけるRab6BとRab28の役割

  Nishimura Noriyuki, Yamamoto Nobuyuki, 長谷川大一郎

  第74回日本癌学会学術総会, Oct. 2015, Japanese, 日本癌学会, 名古屋, Domestic conference

  Oral presentation


• Persistent MRSE infection and CV line-related thrombosis in AML patient in neutropenic phase.

  Mori Takeshi, Minamikawa Syogo, Yamamura S, Fujimura Junya, Horinouchi Tomoko, Yamamoto Nobuyuki, Hirase T, Kubokawa Ikuko, Hayakawa Akira, Nishimura Noriyuki, Iijima Kazumoto

  第77回日本血液学会学術集会, Oct. 2015, Japanese, 日本血液学会, 金沢, Domestic conference

  Oral presentation


• DENNドメイン蛋白質DENND2Aによる神経芽腫発の発症・進展の制御機構

  Yamamoto Nobuyuki, Nishimura Noriyuki, 長谷川大一郎

  第74回日本癌学会学術総会, Oct. 2015, Japanese, 日本癌学会, 名古屋, Domestic conference

  Oral presentation


• Clinical differences between Anaphylaxis children with prehospital remission and exacerbation.

  Ninchoji Takeshi, Matsunoshita Natsuki, Yamamoto Nobuyuki, Nakagawa Taku, Ikeda Mariko, Morisada Naoya, Ishibashi Kazuto, Iijima Kazumoto, Ishida Akihito, Morioka Ichiro

  European Academy of Paediatrics, Sep. 2015, English, EAP, Oslo, ノルウェー, International conference

  Oral presentation


• 骨髄像にて腫瘍細胞の集簇を認め診断に難渋した急性巨核芽性白血病の1例

  東口 佳苗, 松本 久幸, 菊間 知恵, 山下 智江, 野口 依子, 鯉田 祐佳里, 小林 曜子, 城尾 可奈, 中町 祐司, Kawano Seiji, Yamamoto Nobuyuki, Hayakawa Akira

  第16回日本検査血液学会学術集会, Jul. 2015, Japanese, 日本検査血液学会, 名古屋, Domestic conference

  Oral presentation


• 神戸こども初期急病センターにおける同日複数回受診患児についての検討

  石橋和人, 石田明人, 井上祐司, 片山以登, 児玉真美, 植松女久美, 安井美佳, 尾崎美恵, Morioka Ichiro, Morisada Naoya, Ikeda Mariko, Yamamoto Nobuyuki, 松野下夏樹, Ninchoji Takeshi

  第29回日本小児救急医学会学術集会, Jun. 2015, Japanese, 日本小児救急医学会, 大宮, Domestic conference

  Poster presentation


• 左鎖骨部腫瘤を呈した生後6ヶ月の乳児例

  Mori Takeshi, 藤村順也, 堀之内智子, 南川将吾, 平瀬敏志, Yamamoto Nobuyuki, 久保川育子, Hayakawa Akira, Nishimura Noriyuki, Sakakibara Shunsuke, Terashi Hiroto, Iijima Kazumoto

  第265 回 日本小児科学会兵庫県地方会, May 2015, Japanese, 日本小児科学会兵庫県地方会, 神戸, Domestic conference

  Oral presentation


• Neuroblastoma minimal residual disease markers are differentially expressed in peripheral blood and bone marrow samples.

  Uemura Suguru, Yamamoto Nobuyuki, Kozaki Aiko, Yanai Tomoko, Hasegawa Daiichiro, Kawasaki K, Kosaka Yoshiyuki, Hayakawa Akira, Iijima Kazumoto, Nishio Hisahide, Nishimura Noriyuki

  The 11th Asian Society for Pediatric Research, Apr. 2015, English, Asian Society for Pediatric Research, 大阪, International conference

  Poster presentation


• Role of a membrane traffic regulator Rab6B in the development of cancer stem cells in neuroblastoma

  西村 範行, ファム ティファン ヒュエン, ハルトモ トリ ブディ, Yamamoto Nobuyuki, 平瀬 敏志, Hayakawa Akira, 矢内 友子, 長谷川 大一郎, 川崎 圭一郎, 小阪 嘉之, 松尾 雅文, Iijima Kazumoto, Nishio Hisahide

  The 56th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, Nov. 2014, Japanese, the Japanese Society of Pediatric Hematology/Oncology, 岡山, Domestic conference

  Oral presentation


• 化学療法中に虫垂炎を発症した小児悪性腫瘍症例の検討

  Yamamoto Nobuyuki, 山村 智彦, 平瀬 敏志, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, 西村 範行, 會田 洋輔, Hisamatsu Chieko, 前田 貢作, Iijima Kazumoto

  第56回日本小児血液・がん学会学術総会, Nov. 2014, Japanese, 日本小児血液・がん学会, 岡山, Domestic conference

  Oral presentation


• Aldehyde dehydrogenase ALDH1A2 regulates cancer stem cell properties in neuroblastoma.

  Noriyuki Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham, Yamamoto Nobuyuki, Satoshi Hirase, Hayakawa Akira, Tomoko Yanai, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Iijima Kazumoto, Nishio Hisahide

  The 56th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, Nov. 2014, English, the Japanese Society of Pediatric Hematology/Oncology, 岡山, Domestic conference

  Oral presentation


• Prognostic impact of absolute lymphocyte counts at the end of induction in pediatric non-T cell ALL.

  Satoshi Hirase, Daiichiro Hasegawa, Tomoko Yanai, Atsuro Saitou, Aiko Kouzaki, Toshiaki Ishida, Keiichiro Kawasaki, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, Iijima Kazumoto, Yoshiyuki Kosaka

  第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference

  Oral presentation


• Induction of ALDH1A2 expression is critical for cancer stem cell properties in neuroblastoma.

  Noriyuki Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham, Yamamoto Nobuyuki, Satoshi Hirase, Hayakawa Akira, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Yasuhiro Takeshim, Iijima Kazumoto, Nishio Hisahide

  AACR Annual Meeting 2014 (American Association for Cancer Research), Apr. 2014, English, American Association for Cancer Research, San Diago, アメリカ, International conference

  Poster presentation


• 開腹下腫瘍生検時にDamage control手術を行い、術後腹部コンパートメント症候群に対して血液透析下に化学療法を施行した神経芽腫破裂の1例

  Hisamatsu Chieko, 會田 洋輔, 西田 浩輔, 平瀬 敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, 西島 栄治

  第36回近畿小児がん研究会, Feb. 2014, Japanese, 近畿小児がん研究会, 滋賀, Domestic conference

  Oral presentation


• 初診時に血管腫と鑑別を要した右下腿原発乳児線維肉腫の新生児例

  Kubokawa Ikuko, 西田 浩輔, 平瀬 敏志, Yamamoto Nobuyuki, Mori Takeshi, Hayakawa Akira, Ejiri Hirotaka, 西井 達矢, 藤原 周一, 大西 康央, Hara Hitomi, Kawamoto Teruya, Akisue Toshihiro, 大谷 恭子, Sakai Yasuhiro, Hara Shigeo, Hirose Takanori, Itoh Tomoo, 大喜多 肇, Iijima Kazumoto

  第55回日本小児血液・がん学会学術集会, Nov. 2013, Japanese, 日本小児血液・がん学会, 福岡, Domestic conference

  Poster presentation


• メソトレキセート大量療法後の急性腎不全に対し血液浄化療法を施行した若年成人急性リンパ性白血病の1例

  Kubokawa Ikuko, 西田 浩輔, 平瀬 敏志, Yamamoto Nobuyuki, 加藤 威, Mori Takeshi, Hayakawa Akira, Nishi Shinichi, Iijima Kazumoto

  第55回日本小児血液・がん学会学術集会, Nov. 2013, Japanese, 日本小児血液・がん学会, 福岡, Domestic conference

  Poster presentation


• Identification of ALDH1A2 as a critical ALDH isoform in neuroblastoma cells with cancer stem cell phenotype

  Tri Budi Hartomo, Thi Van Huyen Pham, Yamamoto Nobuyuki, Satoshi Hirase, Hayakawa Akira, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Masafumi Matsuo, Takeshima Yasuhiro, Iijima Kazumoto, Nishio Hisahide, Nishimura Noriyuki

  Pediatric Cancer at The Crossroad, Nov. 2013, English, American Association for Cancer Research, San Diego, USA, Purpose: Neuroblastoma is the most common extra-cranial solid tumor that accounts for ~15% of all cancer-related deaths in children. Despite current aggressive therapies, more than half of high-risk neuroblastoma patients have experienced a tumor relapse leading to mostly cancer-related deaths. As in most cancers, recurrent neuroblastoma is primarily driven by chemoresistant ca, International conference

  Poster presentation


• Cytokine changes in a juvenile case with rapidly progressive multicentric Castleman disease.

  Kubokawa Ikuko, Tomoko Yanai, Kousuke Nishida, Satoshi Hirase, Yamamoto Nobuyuki, Toyoshima Daisaku, Nakagawa Taku, Mori Takeshi, Morisada Naoya, Hayakawa Akira, Takeshima Yasuhiro, Hisamatsu Chieko, Yano Yoshihiko, Tatsuya Nishii, Keisuke Nishimura, Gouichi Kageyama, Keiichirou Uehara, Hayashi Yoshitake, Tomoo Ito, Taizo Wada, Akihiro Yachie, Iijima Kazumoto

  第75回日本血液学会学術集会, Oct. 2013, Japanese, 日本血液学会, 札幌, Domestic conference

  Poster presentation


• 乳児血管腫に対するプロプラノロール内服療法の有用性について

  山下 和彦, 赤澤 由子, 山口 由加里, 平瀬 敏志, 加藤 威, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, 矢内 友子, 久米 学, 槇本 博雄, Hirano Takeshi, Hayakawa Akira, Hirai Midori

  第23回日本医療薬学会年会, Sep. 2013, Japanese, 日本医療薬学会, 仙台, Domestic conference

  Oral presentation


• 哺乳不良・体重増加不良にて発症し著明な高カルシウム血症を呈した悪性腎腫瘍の1乳児例

  Kubokawa Ikuko, 加藤 威, 平瀬 敏志, Yamamoto Nobuyuki, 石森 真吾, Ninchoji Takeshi, Nakagawa Taku, Morisada Naoya, Ikeda Mariko, Mori Takeshi, 矢内 友子, Hayakawa Akira, Takeshima Yasuhiro, Iijima Kazumoto

  第27回日本小児救急医学会学術集会, Jun. 2013, Japanese, 日本小児救急医学会, 沖縄, Domestic conference

  Oral presentation


• 積極的治療にて救命し長期間寛解を維持している頭蓋内出血合併急性前骨髄球性白血病の1例

  矢内 友子, 加藤 威, 平瀬 敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, Takeshima Yasuhiro, Iijima Kazumoto

  第27回日本小児救急医学会学術集会, Jun. 2013, Japanese, 日本小児救急医学会, 沖縄, Domestic conference

  Oral presentation


• 抗Ｊｋa自己抗体を検出したＩｇＡ欠 損症を伴うＥｖａｎｓ症候群の一例

  谷歩美, Sugimoto Takeshi, 早川郁代, 橋本誠, 矢内友子, Mori Takeshi, 久保川郁子, 加藤威, 平瀬敏志, Yamamoto Nobuyuki, Hayakawa Akira, Minami Hironobu

  第61回日本輸血・細胞治療学会, May 2013, Japanese, 日本輸血・細胞治療学会, 横浜, Domestic conference

  Poster presentation


• ビタミンB12欠乏性貧血を発症したDown症候群の乳児例

  神吉 直宙, 加藤 威, 平瀬 敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, 矢内 友子, Hayakawa Akira, Morioka Ichiro, Iijima Kazumoto

  第116回日本小児科学会学術集会, Apr. 2013, Japanese, 日本小児科学会, 広島, Domestic conference

  Oral presentation


• 骨髄移植後の造血機能不全に対して同一の非血縁ドナーからの前処置なしで骨髄液再輸注を行い、有効であった慢性活動性EBV感染症の一例

  Mori Takeshi, 加藤 威, 神吉 直宙, 平瀬 敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, 矢内 友子, Hayakawa Akira, Iijima Kazumoto

  第35回日本造血細胞移植学会総会, Mar. 2013, Japanese, 日本造血細胞移植学会, 石川, Domestic conference

  Poster presentation


• 顔貌と胆汁うっ滞をきっかけとして診断に至った Alagille 症候群の1例

  加藤 威, 神吉直宙, 平瀬敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, Ikeda Mariko, 矢内友子, Hayakawa Akira, Iijima Kazumoto

  第 258 回 日本小児科学会兵庫県地方会, Feb. 2013, Japanese, 尼崎, Domestic conference

  Oral presentation


• 顔貌と胆汁うっ滞をきっかけとして診断に至ったAlagille症候群の1例

  加藤 威, 神吉 直宙, 平瀬 敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, Mori Takeshi, Ikeda Mariko, 矢内 友子, Hayakawa Akira, Iijima Kazumoto

  第258回日本小児科学会兵庫県地方会, Feb. 2013, Japanese, 日本小児科学会兵庫県地方会, 尼崎, Domestic conference

  Oral presentation


• 神経芽腫症例におけるmultiple real-time RT-PCR markerを用いた微小残存病変(MRD)解析

  田中愛子, 長谷川大一郎, Tri Budi Hartomo, Yamamoto Nobuyuki, 宮田憲二, 越智智史, 斎藤敦郎, 山下達也, 石田敏章, 川崎圭一郎, 松尾雅文, Thi Van Huyen Pham, 大橋浩基, Mori Takeshi, 矢内友子, Hayakawa Akira, Takeshima Yasuhiro, 小阪嘉之, Iijima Kazumoto, Nishio Hisahide, Nishimura Noriyuki

  第54回日本小児血液・がん学会学術集会, Dec. 2012, Japanese, 日本小児血液・がん学会, 横浜, 【諸言】神経芽腫の予後は全体的には改善したが、進行例の長期予後は未だ不良であり、微小残存病変 (MRD) の正確 な評価が予後改善には不可欠である。今回我々は、MRD 検索の感度向上のため、multiple real-time RT-PCR marker を 用いた MRD 測定系を樹立し、各マーカーの感度、臨床情報との相関について解析を行った。【方法】既報の 11 の MRD マーカー (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B, TH) について、神経芽腫 tumor initiating cells を段階的に希釈して検量線を作成し 、基準値を設定した。倫理委員会の 承認の下、2011 年 2 月から 2012 年 6 月までに当科で経験した, Domestic conference

  Oral presentation


• 電撃性紫斑病にて発症した先天性Protein C欠損症の新生児例

  Mori Takeshi, Shibata Akio, Koda Tsubasa, 三輪明弘, Yokota Tomoyuki, Morioka Ichiro, Kawano Seiji, 中町祐司, 岡崎葉子, 加藤 威, 神吉直宙, 平瀬敏志, Yamamoto Nobuyuki, Kubokawa Ikuko, 矢内友子, Hayakawa Akira, 横山直樹, Iijima Kazumoto

  第54回日本小児血液・がん学会学術集会, Nov. 2012, Japanese, 横浜, Domestic conference

  Poster presentation


• 初診時に高Ca血症を認めた小児悪性腫瘍3例の臨床的検討

  Kubokawa Ikuko, 加藤 威, 神吉直宙, 平瀬敏志, Yamamoto Nobuyuki, Ninchoji Takeshi, Mori Takeshi, 矢内友子, Hayakawa Akira, Iijima Kazumoto

  第54回日本小児血液・がん学会学術集会, Nov. 2012, Japanese, 横浜, Domestic conference

  Poster presentation


• 当院における造血幹細胞移植後のリンパ球回復とその予後の検討

  平瀬敏志, 神吉直宙, 加藤 威, 松野下夏樹, Yamamoto Nobuyuki, Kubokawa Ikuko, 矢内友子, Hayakawa Akira, Iijima Kazumoto

  第74回日本血液学会学術集会, Oct. 2012, Japanese, 東京, Domestic conference

  Poster presentation


• 免疫性血小板減少症治療中の重症肺炎・ARDSに対しECMOを2回長期導入し救命し得た幼児例

  平瀬敏志, 矢内友子, Hisamatsu Chieko, 加納寛也, 谷岡 怜, 北 博志, 神吉直宙, 加藤 威, 松野下夏樹, Yamamoto Nobuyuki, Kubokawa Ikuko, 粟野宏之, Mori Takeshi, Hayakawa Akira, Takeshima Yasuhiro, Iijima Kazumoto

  第45回日本小児呼吸器疾患学会, Sep. 2012, Japanese, 旭川, Domestic conference

  Oral presentation


• A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509.

  Kotani Yoshikazu, Miyako Satouchi, Masahiko Ando, Kazuhiko Nakagawa, Yamamoto Nobuyuki, Yukito Ichinose, Yuichiro Ohe, Makoto Nishio, Toyoaki Hida, Koji Takeda, Tatsuo Kimura, Koichi Minato, Akira Yokoyama, Shinji Atagi, Taro Shibata, Haruhiko Fukuda, Tomohide Tamura, Nagahiro Saijo

  2012ASCO meeting, Jun. 2012, English, American Society of Clinical Oncology, Chicago, Background: IP is the standard treatment for ED-SCLC, however often cause severe diarrhea. AP have shown promising activity in SCLC with fewer diarrhea. We conducted a phase III trial comparing AP with IP. Methods: Eligibility criteria included patients (, International conference

  Keynote oral presentation


• 乳児血管腫に対するβ遮断薬の治療経験

  矢内友子, 神吉直宙, 加藤 威, 松野下夏樹, 平瀬敏志, Yamamoto Nobuyuki, Ejiri Hirotaka, Kubokawa Ikuko, 三輪明弘, Mori Takeshi, Morioka Ichiro, Hayakawa Akira, Takeshima Yasuhiro, Iijima Kazumoto

  第256回日本小児科学会兵庫県地方会 神戸 2012.5.26, May 2012, Japanese, 神戸, Domestic conference

  Oral presentation


• A case of alveolar rhabdomyosarcoma mimicking acute leukemia of admission

  Yamamoto Nobuyuki, Yamamoto Nobuyuki, 平瀬 敏志, 平瀬敏志, 松野下夏樹, Mori Takeshi, Mori Takeshi, 矢内 友子, 矢内友子, Hayakawa Akira, Hayakawa Akira, Nishimura Noriyuki, Nishimura Noriyuki, Takeshima Yasuhiro, Takeshima Yasuhiro, Iijima Kazumoto, Iijima Kazumoto, 松尾雅文, 松尾 雅文

  第53回日本小児血液・がん学会学術集会, Nov. 2011, Japanese, 日本小児血液・がん学会, 前橋, Domestic conference

  Poster presentation


• 小児同種造血幹細胞移植におけるGFRの指標としての血清シスタチンCの有用性の検討

  矢内 友子, 平瀬 敏志, 松野下 夏樹, Yamamoto Nobuyuki, Ninchoji Takeshi, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, 松尾 雅文

  第73回日本血液学会学術集会, Oct. 2011, Japanese, 日本血液学会, 名古屋, Domestic conference

  Others


• Place of Death of Pediatric Cancer Patients in Japan

  Yanai T, Hirase S, Matsunoshita N, Yamamoto Nobuyuki, Ninchoji Takeshi, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, Takeshima T, Iijima Kazumoto, Matsuo MYanai T, Hirase S, Matsunoshita N, Yamamoto Nobuyuki, Ninchoji Takeshi, Kubokawa Ikuko, Mori Takeshi, Hayakawa Akira, Takeshima T, Iijima Kazumoto, Matsuo M

  the 43rd Congress of the International Society of Pediatric Oncology, Oct. 2011, English, オークランド, ニュージーランド, International conference

  Others


• 当院におけるユーイング肉腫ファミリー腫瘍の治療成績

  Yamamoto Nobuyuki, Ninchoji Takeshi, Kubokawa Ikuko, Mori Takeshi, 矢内 友子, Hayakawa Akira, 松尾 雅文

  第114回日本小児科学会学術集会, Aug. 2011, Japanese, 日本小児科学会, 東京, Domestic conference

  Others


• バルガンシクロビル内服治療により聴性脳幹反応異常が改善した先天性サイトメガロウィルス感染症の2例

  Matsuo Kiyomi, Matsuo Kiyomi, Morioka Ichiro, Morioka Ichiro, Koda Tsubasa, Koda Tsubasa, Yamamoto Nobuyuki, Yamamoto Nobuyuki, Yokota Tomoyuki, Yokota Tomoyuki, 藤岡 一路, 藤岡一路, 森川悟, 森川 悟, 三輪 明弘, 三輪明弘, Shibata Akio, Shibata Akio, Hayakawa Akira, Hayakawa Akira, 横山直樹, 横山 直樹, 松尾 雅文, 松尾雅文

  第253回日本小児科学会兵庫県地方会, May 2011, Japanese, 日本小児科学会兵庫県地方会, 神戸, Domestic conference

  Oral presentation


• トロンボポエチン受容体作動薬が有効であった何時性慢性ITPの1歳男児例

  平瀬 敏志, 松野下 夏樹, Yamamoto Nobuyuki, Ninchoji Takeshi, Mori Takeshi, 矢内 友子, Hayakawa Akira, 松尾 雅文, Iijima Kazumoto

  第25回近畿小児科学会, Mar. 2011, Japanese, 近畿小児科学会, 京都, Domestic conference

  Others

• 神経芽腫のがん微小環境制御における間葉系幹細胞の役割に関する研究

  西村 範行, 山本 暢之

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2021 - 31 Mar. 2024

  神経芽腫は、神経堤細胞が交感神経系へ分化する過程で発生する代表的な小児難治性固形がんで、小児がん死亡の約1/6を占めている。特に、高リスク神経芽腫患者の大部分は、一旦は治療に反応して寛解を達成するが、その半数以上が再発して極めて治療困難になり、その長期生存率は未だ50%に達していない。これには、治療後に微小残存病変(MRD)として体内に残存したがん細胞が再活性化し、異なる形質を示すようになることが重要だと考えられる。化学療法や放射線療法は、治療後に亜致死となったがん細胞および微小環境中の間質細胞に細胞老化を誘導(治療誘発細胞老化：TIS)し、エクソソームやサイトカイン等の分泌(細胞老化随伴分泌現象：SASP)を促していることが明らかになり、治療困難のメカニズムを理解するためには、がん細胞の異なる形質の発現を担う分泌因子の同定が必須だと考えられる。これまでに申請者らは、MRDの新規評価法を開発してその動態を明らかにすると共に、神経芽腫細胞と微小環境の主要な構成細胞で分泌活性の高い間葉系幹細胞(MSC)との相互作用を明らかにしてきた。そこで本研究では、MSCのSASPによって分泌される分子を同定し、その機能を明らかにすることを試みる。本年度の研究では、高リスク神経芽腫治療に用いられるシスプラチン(CDDP)やテモゾロミド(TMZ)によるMSCのSASPによって分泌される分子群を同定した。


• Role of Rab family small G proteins in the regulation of neuroblastoma microenvironment

  Nishimura Noriyuki

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2017 - 31 Mar. 2020

  High-risk neuroblastoma causes more than 50% relapse and shows therapy resistance. This is mainly due to tumor heterogeneity that is induced by tumor microenvironment and therapy stress and controlled by Rab family small G proteins (Rabs), key regulators of membrane traffic. In the present study, we have identified some members of Rabs, which potentially control the secretion of growth factors and tumor markers in neuroblastoma microenvironment.

  Competitive research funding


• Role of DENND2A for development of neuroblastoma

  YAMAMOTO NOBUYUKI, Nishimura Noriyuki, Mori Takeshi, Kosaka Yoshiyuki

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2016 - 31 Mar. 2018, Principal investigator

  Neuroblastoma is a typical recurrent and refractory tumor in children and its long-term survival remains less than 40%. Neuroblastoma relapse is caused by activation of chemo-resistant cancer stem cells (CSCs). Key regulators of intracellular vesicle trafficking, DENN domain proteins, were implicated in this process. In this study, a member of DENND domain proteins DENND2A and its target Rab family small G protein Rab9B were found to be involved in the development and progression of neuroblastoma.

  Competitive research funding


• Role of DENN domain proteins in the development of neuroblastoma cancer stem cells.

  Yamamoto Nobuyuki, Nishimura Noriyuki, Hayakawa Akira, Kosaka Yoshiyuki, Yanai Tomoko

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2014 - 31 Mar. 2016, Principal investigator

  More than half of high-risk neuroblastoma patients experience tumor relapses and less than 40% can expect a long-term survival. Intracellular vesicle transport seems to play an important role on the development of neuroblastoma cancer stem cells that are responsible for tumor relapses. In this study, we focused on DENN domain proteins, regulators of intracellular vesicle transport, and revealed that a member of DENN domain proteins is involved in the progression of neuroblastoma.

  Competitive research funding